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THE PRODUCTION OF DESIGNED POTENTIAL PROTEIN CONTRAST AGENTS 
AND THEIR ENCAPSULATION IN ALBUMIN MICROSPHERES 
by 
JULIAN A. JOHNSON 
Under the Direction of Drs. Jenny J. Yang and Zhi-ren Liu 
ABSTRACT 
 
Using protein design, a series of metal binding proteins have been designed, 
allowing the local factors that contribute to metal affinity and thermostability to be 
studied.  Those proteins with the highest metal binding affinities had the lowest apo-form 
Tm and the largest ∆Tm upon metal binding.  In this thesis, major steps have been taken 
toward applying the engineered protein to MR imaging.  The progress of magnetic 
resonance imaging is hindered by low specificity and rapid elimination of FDA-approved 
MRI contrast agents.  The engineered protein contrast agent has been conjugated to a 
cancer-specific targeting peptide and encapsulated in albumin microspheres to provide 
tandem passive and active tumor targeting.  Also, a simple, high-yield purification 
method has been developed. 
INDEX WORDS:  Microspheres, CD2, Protein design, Contrast agent 
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1 Introduction: Motivation and Hypotheses 
 
1.1 Design of Ca(II)/La(III) binding Protein with Different Charged Ligand 
Residues 
CD2.7E15 is a designed metal binding protein based on the N-terminal domain of 
the cell adhesion protein cluster of differentiation 2 (CD2.d1) (1).  Site directed 
mutagenesis was used to create a metal binding site on the surface of the protein.  
Initially the intention was to utilize this designed metal binding protein to understand the 
local factors associated with Calcium binding (2, 3).  Calcium signaling is an essential 
part of life, but the actual process of calcium binding is poorly understood.  Factors that 
are suspected to play a role in calcium binding affinity include the ligand type, the 
electrostatic environment, the net charge of the protein and the metal-binding geometry.  
Some of the problems that complicate the study of calcium binding in nature include 
metal-to-metal interactions and multiple binding sites (e.g.: calmodulin with its four 
binding loops).  Lanthanide ions share coordination properties that are similar to those 
required by Ca (II); therefore, lanthanides are often used to probe calcium binding sites in 
proteins.  
 In our lab, we have taken two approaches to studying calcium and lanthanide 
binding in single site systems.  The first approach is to insert the binding loops of a 
calcium binding protein that occurs in nature (such as calmodulin) into proteins that do 
not naturally bind calcium ions.  We call this the grafting approach.  Our lab has 
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successfully studied the calcium binding affinity of all four calcium binding loops present 
in calmodulin using this approach.  Our lab is also looking to use this approach to design 
GFP-based calcium sensors. 
  The second approach is called the design approach. The design approach utilizes 
computer algorithms to locate potential sites for binding ligands within a stable host 
protein that does not have a metal binding site. 
The first objective of this thesis is to generate single site systems that will 
eliminate cooperativity and global conformational change so that the local factors can be 
studied.  In the future it may be possible to design proteins that fold or unfold in response 
to changes in local calcium concentration.  Also, designing calcium binding proteins has 
given our lab significant insight into the features of calcium binding sites.  Our lab 
recently located the calcium binding site of the newly discovered calcium sensing 
receptor (CaSR).  In addition to studying the effects of net charge and ligand type on 
calcium/lanthanide binding affinity, we would like to relate the trends observed in net 
charge, ligand type, and metal binding affinity to any possible trends in calcium 
conferred stability.  In nature, calcium often plays a role in stabilization.  In the case of 
the bacterial protease thermolysin, there is a very significant Tm difference between the 
apo and the calcium loaded enzyme. The objective of the research discussed in chapter 2 
is to carry out conformational analysis of 7E15 and its charged variants in the presence 
and absence of bound metal and to determine the thermal stability of these variants with 
and without metal. 
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1.2 Use of Designed Protein as a MRI Contrast Agent 
Due to calcium’s spectroscopically silent nature and the similarities between 
lanthanide and calcium coordination geometry, lanthanide metals (e.g. Gadolinium, 
Terbium and Lanthanum) are used to probe the metal binding site using fluorescent 
resonance energy transfer from tryptophan residues (4).  Our designed protein, which is 
referred to as CD2.7E15 or simply 7E15, has a high affinity for gadolinium (2, 3, 5) and 
our lab later discovered the need for high affinity Gadolinium chelators in magnetic 
resonance imaging (MRI).   
Magnetic resonance imaging is growing in popularity in the clinical and research 
arenas due to its non-invasive nature and its potential to produce high clarity images (6-
8).  MRI boasts numerous advantages over other imaging techniques such as 
fluorescence, X-ray, and positron emission tomography:  MRI provides a true volume 
rendering, is unhindered by tissue depth, produces no toxic by-products, uses no harmful 
radiation, and is not affected by light scattering or photobleaching (9, 10).  MRI provides 
a three dimensional representation, the clarity of which is a function of the difference in 
relaxation time between water molecule protons in adjacent, physiologically distinct 
tissues.  There is considerable research directed toward the development of molecules 
capable of enhancing the difference in relaxation time of nearby water protons.  Members 
of this diverse class of molecules are called MRI contrast agents and their potency is 
measured by their relaxivity (R1 or R2 with units of M-1s-1).  To date, the relaxivity of 
contrast agents has failed to reach levels that are theoretically possible.  The relaxivity of 
current FDA approved contrast agents is 20 to 50 times lower than the theoretically 
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possible value, the most popular of which is Gd-DTPA.  Since relaxivity is positively 
correlated with molecular radius, the designed metal binding protein CD2.7E15 possesses 
a relaxivity that is 10 to 20 times higher than that of Gd-DTPA, the most widely used 
MRI contrast agent. 
Because of its high relaxivity, use of CD2.7E15 rather than Gd-DTPA is 
favorable because less contrast agent (in mg per kg of bodyweight) would be required to 
produce a sufficient image.  Additionally, Gd-DTPA is considered a blood pool agent, 
meaning it does not have a specific partitioning to any particular organ or tissue.  The 
construct CD2.7E15 can be engineered to include on or more specific peptide tags.  In 
this thesis, a CD2.7E15 construct conjugated to bombesin, is studied (referred to 
throughout this thesis as CD2.7E15.bom or 7E15-bom).  The bombesin tag is an analog 
of gastrin releasing peptide, which possesses a high affinity for the gastrin releasing 
peptide receptor  (11-13).  The gastrin releasing peptide receptor is overexpressed on 20-
40 % of colon cancer cells and 30-60% prostate cancer cells (14-16).  The receptor may 
also be overexpressed in some lung carcinomas (12, 17) and some ovarian carcinomas 
(18).  The receptor number can reach 1x106 per cell (19).  Current methods of MR 
imaging cannot discern anatomical differences that are less than 1-2 mm in diameter.  If 
the specific tag can enrich the contrast agent in surrounding tissues, the intensity and 
clarity of MRI can be improved to detect tumor metastases <2 mm.  Several problems 
with this research venture will be discussed in this thesis, including the potential 
pharmacokinetic manipulation of the contrast agent, and the production (expression and 
purification) of the protein contrast agents. 
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1.3 Production of Engineered Proteins 
The copious research necessary to move this project from theoretical prospect to 
the clinic will require rapid, reliable, high throughput production of CD2.7E15.  Since the 
early stages of CD2.7E15 studies, CD2.7E15 was expressed in the pGEX-2T vector, 
which confers an N-terminal glutathione-S-transferase (GST) tag, facilitating affinity 
column purification using a column containing sepharose beads covalently conjugated to 
glutathione (the GST substrate).  GST is a 27 kDa protein known as glutathione-S-
transferase.  7E15 is approximately 11 kDa and proteins of this size can have difficulty 
becoming soluble in the bacterial cytoplasm.  The size (27 kDa) and N-terminal 
conjugation of GST probably facilitates the solubilization of the entire fusion protein 
(20).   
There are several disadvantages to the current purification method.  GST does not 
always fold properly, which prevents GST from binding to the glutathione-sepharose 
beads during affinity column purification (the initial step of purification in this 
procedure).  In fact, during the purification procedure a considerable amount of protein 
remains in the cell pellet after sonication and centrifugation, presumably this is denatured 
and/or aggregated insoluble fusion protein.  Also, fusion protein is detected in the waste 
after affinity column purification, which may be soluble fusion protein that has been 
rendered nonfunctional during expression or the purification procedure.  The size and 
disulfide bonds of GST result in a protein that does not refold well, so recovering the 
entire fusion protein would be tedious.  The caveat is that CD2.d1 is a small protein with 
a very stable IgG fold, which generally refolds very well (21).  Presumably, 7E15 will 
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refold well, since it shares a nearly identical secondary and tertiary structural 
arrangement with CD2.d1 and differs by only three amino acid substitutions (5).  Finally, 
the GST fusion system requires that 7E15 be cleaved from GST using thrombin, an 
expensive enzyme, which, although highly active on a defined amino acid sequence, 
retains some measurable activity on virtually all Arg-Gly and Gly-Arg bonds (22, 23).  
Deliberate exposure to thrombin may result in further loss of valuable product and an 
unforgiving purification procedure.  The average yield of CD2.7E15 purified using the 
GST fusion system is 6 mg/L cell culture and the average yield of CD2.7E15-bombesin 
purified using this method is approximately 3 mg/L cell culture (Fig 2.1). 
Bacterial expression has the potential to produce enormous amounts of protein 
when overexpression is induced.  Because of the relative size of GST to 7E15—27 kDa 
and <12 kDa, respectively—the GST-fusion expression system devoted most of the 
expression resources to GST rather than 7E15.  Also, as aforementioned, GST does not 
refold well.  A study by Lichty et al surveyed the cost of protein purification and found 
that, GST-fusion proteins were inferior to histidine tagged proteins (24).  The most 
popular form of the histidine tag (histag) consists of six histidine residues in sequence.  
These residues bind to nickel immobilized by a chelator bound to sepharose or agarose 
beads.  The histag’s small size allows most of the expression effort to be devoted to the 
target protein.  In the event of aggregation, it is hypothesized the histag probably will not 
interfere in the refolding process to the extent that GST does; the histag has been shown 
to have no significant effect on crystal structures (25) and several purification procedures 
have been developed to refold histidine tagged proteins (26).  Therefore, the second 
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objective of this study is to develop a rapid, efficient protein purification method to 
produce a large quantity of engineered proteins. 
1.4 Encapsulation of Engineered Proteins in Albumin Microspheres 
In addition to the problems encountered in our current protein production system, 
the formulation of our contrast agent has yet to be optimized for tumor-specific delivery 
of sufficient amounts of our contrast agent.  Typically, injected drugs are found in their 
highest concentrations in the liver, spleen, and kidney.  Protein drugs are no exception 
(see the appendix of this thesis for a detailed review of the biodistribution of protein 
drugs) (27-31).  Since MRI contrast enhancement is highly dependent on local 
concentration of the contrast agent, nonspecific accumulations in the kidney, liver and 
spleen are highly undesirable and may possibly hinder the detection of small tumors near 
these organs.  To alter the pharmacokinetics, albumin microspheres and targeting 
peptides will be used.  Albumin microspheres were first described in 1974 by PA Kramer 
as a means for achieving specificity in drug delivery (32, 33).  Microspheres shift the 
Biodistribution to the following: the vasculature, by increasing the circulation time; the 
lungs, via selective phagocytosis by lung associated macrophages; and inflamed tissues 
or tumors, due to enhanced capillary permeability in these regions (34-37).  Albumin 
microspheres are immunologically inert, nontoxic, and degrade into nontoxic amino acids 
(38-41).  There are several means to prepare microspheres, but the most homogenous is 
spray-drying.  Spray-drying requires exposure to >100 °C to rapidly evaporate moisture 
from the drug-albumin preparation.  Spray drying has been used on several proteins with 
disturbances in structure and function ranging from negligible (42-44) to greater than 
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50% inactivation (45-47).  The effect of spray drying on the folding, metal binding 
properties, and, perhaps most importantly, the relaxivity of the protein contrast agent 
7E15 is examined in this thesis. 
 The third objective of this project is to develop high throughput purification 
methods for the designed protein Gd-chelating MRI contrast agents and to test the effect 
of albumin encapsulation on the Biodistribution and relaxivity of these molecules.  Each 
topic will be explored in detail throughout Part I of this thesis.     
1.5 Overview of the organization of this thesis 
Chapter 2 discusses the effect of net charge and ligand type on calcium binding 
affinity and calcium conferred thermal stability.  The research directed towards 
determining the metal binding affinities was largely done by Dr. Anna Wilkins Maniccia 
for her PhD dissertation (Georgia State University Department of Chemistry, summer 
2005), and Dr. Wei Yang (post-doctoral associate in Dr. Jenny J Yang’s lab, 1998-2007).   
Chapter 3 describes the development of a novel purification procedure for the 
designed protein based MRI contrast agents, while Chapter 4 describes the procedures 
necessary to encapsulate them in spray dried albumin microparticles.  Chapter 5 focuses 
on the biophysical characterization of the purified histidine tagged CD2.7E15 before and 
after spray drying.   
Chapter 6 Summarizes the major findings from part one of the thesis (chapters 2-
5) 
Chapter 7 introduces the protein beta-2-microglobulin and its importance in 
prostate cancer metastases.  Chapter 8 entails the procedures directed towards beta-2-
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microglobulin expression and purification.  Chapter 9 describes the efforts towards 
inserting a histidine tag in the C-terminal of this protein.   
Appendix I: Chapter 10 describes the efforts to express a single-chain anti-HER-2 
antibody in E.coli and the purification steps necessary to purify the protein. 
Appendix II: Chapter 11 is a review entitled Biodistribution of Protein Drugs.  
The review describes the general trends in metabolism, elimination, and distribution 
observed when protein drugs are administered to mammals.  The review mostly focuses 
on intravenous administration.  
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2 The Effect of Net Charge and Ligand Type on the Thermal Stability of Calcium 
Binding Proteins 
Calcium binding sites are generated using site directed mutagenesis to change 
wild type residues according to the necessary parameters.  In the case of CD2.7E15, the 
desired coordination geometry is a pentagonal bipyramidal arrangement with an oxygen 
atom at each vertex (Fig 2.1).  All work presented in this work was done on designed 
calcium binding proteins.   
 Domain one of CD2 (CD2.D1) was chosen as the host protein for our engineered 
calcium binding sites.  The topology of domain CD2 is similar to the calcium-dependent 
cell adhesion protein Cadherin.  The size of CD2-D1 (99 amino acid residues) allows for 
easy expression and purification.  CD2 has been shown to withstand mutations at forty 
different residues without significant deviations from the native fold. CD2 maintains its 
native fold through a wide pH range (pH 1 – 10) and salt concentrations (0 - 4 M).  
Finally, NMR and X-ray structures are available for CD2 so that biophysical analysis 
results can be compared to wild type data.  These characteristics make CD2 an excellent 
scaffold for our designed and grafted calcium binding sites (Fig 2.1). 
 Previous studies done by Dr. Anna Wilkins-Maniccia (ICPMS, Tb (III) 
competition, ITC) have shown that 7E15 has a calcium binding affinity in the sub-
micromolar range.  The binding site of 7E15 has a net charge of negative five.  According 
to the acid pair hypothesis outlined by Reed and Hodges (1980), EF-hand (class one) 
calcium binding sites with a net charge of negative four are stronger than calcium binding 
sites of other net charges (-2, -3, or -5) provided that the negatively charged ligands are at 
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opposite vertices in the coordination sphere (eg:-x, x and –y, y). CD2.7E15 is a class two 
calcium binding protein.   We would like to explore the effects of net charge on our class 
of binding site (class two).  Our lab has designed variants of CD2.7E15 with binding 
ligands mutated from negatively charged ligands (Glu or Asp) to similar neutral binding 
ligands (Gln or Asn).  These mutants are called EEDDN, EENDN, and NENDN after the 
single-letter code for the binding ligands.   
Table 2.1   
The residues composing the metal binding sites in 7E15 and its variants.  The 
original residues of wild type cd2.d1 are shown in the first row. 
 
  
   
 
 
 
 
 
 
The variants of 7E15 could also allow the study of the effects of different binding 
ligands in calcium binding affinity.  Variant EEDDQ was designed so that its binding 
affinity could be compared to variant EEDDN.  These variants have net charges of 
negative four and differ only in the residue at the 64th position.  Variant EEDDE was 
designed so that its binding affinity could be compared to 7E15.  Both of these proteins 
-2NDNENNENDN
-3NDNEEEENDN
-4NDDEEEEDDN
-4QDDEEEEDDQ
-5EDDEEEEDDE
-5DDDEE7E15
-1KDLENWt CD2.d1
Net charge6462585615protein
Green= positive Blue= neutral Red= negative
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have a net charge of negative five and they differ only in the residue at the 64th position.  
7E15 has an aspartate while EEDDE has a glutamate.   
  The table below shows the position of the original residues in CD2, the potential 
binding ligands of CD2.7E15, and the corresponding residues in the five variants.    
Variants of 7E15 were thermally denatured in the presence and absence of calcium 
(1mM EGTA or 10mM CaCl2) to determine the Tm in various conditions.  Several 
variants were analyzed in the presence of 50 uM Terbium Chloride (TbCl3).  We will 
ultimately use these trends to generalize the effects of net charge and ligand type on 
metal binding affinity and calcium-conferred thermal stability.   
2.1 Materials & Methods 
2.1.1 Cloning and Molecular Biology 
All variants were mutated by Dr. Anna Wilkins Maniccia.  The details are found 
in her PhD Dissertation (Summer 2005, Georgia State University Department of 
Chemistry).  The 7E15 sequence was inserted between the BamH1 and the EcoR1 
restriction sites of the pGEX-2T vector (GE Healthcare/Pharmacia Biotech).   
2.1.2 Transformation 
To begin the procedure, a 1.5ml eppendorf tube containing approximately 100 uL 
desired competent cells (BL21 (DE3) for expression, DH5α for DNA purification) was 
obtained from a stock of competent kept at -80° C.  The cells were placed on ice to thaw 
and aliquotted into two 50 µL samples.  One sample receives 0.5-1.0 µl of desired 
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plasmid DNA while the other did not receive DNA (this is the negative control).  The 
thawed cells and DNA were mixed by pipetting up and down or gently flicking the 
bottom of the tube.  The cells were left on ice for at least thirty minutes after the addition 
of DNA.  The heat shock was done by placing the cells in a 42 °C water bath for ninety 
seconds and then putting the cells back on ice for two minutes.  Then, 50 µL LB media 
was added and the media was mixed with the cells by pipetting up and down or by gently 
flicking the bottom of the eppendorf tube.  The tubes were then incubated at 37 °C for 30 
minutes.  50 µL of the solution was added to desired agar plates (LB-Amp plates for 
expression) and streaked onto the plates with a sterile triangle.  The plates were then 
incubated at 37° C overnight.  The following morning, the plates were wrapped in 
parafilm and placed upside-down in the refrigerator to retard drying of the agar gel.  No 
plates were kept longer than one month. 
2.1.3 Protein Expression of CD2.7E15 and its Variants 
A single successfully transformed colony was inoculated into 500 mL LB media 
containing 100 mg/L ampicillin.  The colony was allowed to grow overnight at 37 °C and 
180 to 220 rpm agitation.  50 to 100 mL overnight culture was inoculated into 1 L fresh 
LB medium (100 mg/L ampicillin).  Expression at 30 or 37 °C was monitored by 
measuring the light scattering of the media (O.D.600nm).  When the O.D.600nm=0.8 to 1.0, 1 
mL of 1 M IPTG solution was added to the growth to induce protein expression.  After 
three (37 °C expression) to five hours (30 °C expression), the cells were harvested by in 
500 ml bottles at 7 krpm for 15-20 minutes using a GS3 rotor.  The cell pellets were 
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collected using a spatula and less than 5 ml PBS buffer and placed in a 50 ml falcon tube 
and stored at -20 °C for purification at a later date. The supernatant was discarded. 
2.1.4 Protein Purification 
2.1.4.1 Affinity Column Purification of GST-fusion protein-  
The desired cell pellet was thawed out on ice or in cold water.  20-50 ml lysate 
buffer per 2L culture pellet was added to re-suspend the cell pellet. Also, DTT was added 
to this mixture to a final concentration of 5µM.  This solution was sonicated 4-5 times for 
~60 seconds using a Branson 450 Sonifier with the duty cycle set on 90 with 1-5 minutes 
between sonications.  The solutions were kept on ice during sonications.  The solutions 
were centrifuged in 50 ml tubes at 17 krpm for 20 minutes using the S34 rotor after 
sonications.  The supernatant is then filtered with a 0.45 µm filter.  At this point a sample 
was collected for analysis using SDS-PAGE.  The supernatant was placed on ice before 
gravity binding to the Glutathione agarose bead affinity columns.  At this point a 20 µl 
sample of the flow through is taken for analysis using SDS-PAGE.  The flow through 
was then passed over the columns a second time for further binding.  Then the columns 
were washed with 10-20 ml 1X PBS buffer.  A 20 µl sample of the beads was taken at 
this point for analysis using SDS-PAGE.  Usually a 1:5 BioRad protein assay is used to 
determine whether or not any fusion protein was bound to the beads.  If the fusion protein 
has bound (indicated by a color change from copper to deep blue), cleavage of the fusion 
protein was done using thrombin protease (20 µl per column thrombin and 3-4 ml 1X 
PBS buffer per column).  The cleavage was done for 3-12 hours at room temperature.  
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The columns were then washed with 20-50 ml 1X PBS buffer per column and allowed to 
elute fusion protein.  At this point the elution was checked with 1:5 BioRad protein assay 
to determine if protein is being eluted.  Also, a 20 µl sample was taken from the beads as 
well as the elution for analysis using SDS-PAGE.  The elution was then concentrated 
using an Amicon brand concentrating apparatus (180 ml) with a 3 kDa molecular weight 
cutoff membrane.  Solutions are concentrated to 7-10 ml.  Further purification was using 
size exclusion and/or ion exchange chromatography. 
2.1.4.2 Size Exclusion Chromatography 
6-10 ml of elution from affinity column purification was injected into FPLC 
system.  When the elution volume was greater than 20 ml the elution was concentrated 
using an Amicon high pressure concentrating apparatus and an Amicon membrane filter 
before injection.  Samples are filtered with a 0.45 uM filter before injection.  Proteins 
were purified using a size exclusion column and the concentration of each fraction was 
measured using the UV absorbance (280 nm) and the molar extinction coefficient of WT 
CD2 (11700 M-1 cm-1). 
2.1.4.3 Purification using HiTrap SP HP column-  
CD2 variants are purified according to isoelectric point after being purified in our 
G75 size exclusion columns.  First, the fractions containing protein are treated with acetic 
acid to lower the pH to the 3-4 range.  The proteins are bound to the column in 50 mM 
sodium acetate/acetic acid buffer solution (pH 4.5) referred to as buffer A.  Our FPLC 
machine is programmed to allow multiple 10 ml sample injections.  Proteins are eluted 
 16
with 50 mM Tris-HCl (pH 8) referred to as buffer B.  The concentration is determined 
using the UV absorbance (280 nm) and the molar extinction coefficient of WT CD2 
(11700 M-1 cm-1). 
2.1.5 Secondary Structure analysis: Far UV Circular Dichroism-  
Samples of the protein solution were prepared in 10 mM TRIS buffer with a pH 
of 7.4.  Trials were done in the presence of 10 mM CaCl2 to observe the effect of bound 
calcium to conformation.  Trials were also done in the presence of 10 mM EGTA to 
observe the conformation of the variants in the absence of calcium.  All samples were 
approximately 20 µM protein.  Samples were allowed to mix at 4°C for thirty minutes 
after being prepared.  All scans were done in a quartz 200 mm UV cell.  The samples 
were scanned from 260 nm to 200 nm.  Four to six scans were taken and averaged to get 
one spectra.  Scans were done at 50 to 100 nm per minute.  After the scans were taken, a 
scan of the buffer used was subtracted from the protein spectra.    
2.1.6 Determining Tm using Far UV Circular Dichroism - 
Scans were taken at each the desired temperature interval.  The scans were done 
in six accumulations and a 100 nm/min scanning speed.  Thermal denaturation was done 
in the presence and absence of Ca (II) (10 mM CaCl2 vs. 1 mM EGTA).  Thermal 
denaturation scans were also taken in a 50 uM Tb(III) solution in order to compare 
terbium-conferred thermal stability to calcium-conferred thermal stability.  The fractional 
change wass plotted against the temperature to obtain a Tm (using Kaleidagraph ™ 
software).  
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2.1.7 Tryptophan Fluorescence 
The tertiary structure of CD2.7E15 and its charged variants was investigated using 
tryptophan fluorescence.  2 µM protein samples in 10 mM PIPES, pH 6.8 or 20 mM 
PIPES, 10 mM KCl, pH 6.8 were excited at 282 nm and the emission spectra of 
tryptophan residues was observed from 300 to 400 nm.  All measurements were taken at 
room temperature (approximately 27 °C) 
2.1.8 Surface Potential Calculations 
Surface potential calculations were done by Dr. Wei Yang.  The protein surface 
potential and energy of CD2.7E15 variants were calculated using the DelPhi program 
based on model structures. The model structures of CD2.7E15 with the Ca2+ 
coordinations were generated by the design program and the structures of the other 
variants were generated by the program SYBYL (Tripos Co.) from CD2.7E15. The 
protons were first added in the pdb files using SYBYL. The apo-form structures simply 
removed the coordination of Ca2+ and the Ln3+-loaded form structures simply replaced 
the Ca2+ with a Tb3+ at the same coordination. In DelPhi calculation (48-50), the interior 
and exterior dielectric constants were set to be 4 and 80, respectively. A salt 
concentration of 10 mM in solution was used. To compare the energy output from the 
DelPhi program, only the energy of the protein part was used. That is, the energy on the 
Ca2+ or Tb3+ was subtracted for the metal-binding forms of the proteins. 
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2.2 Results & Discussion 
As shown in Figure 2.1, CD2.7E15 is a rational designed Ca2+-binding protein with 
an engineered Ca2+-binding site at the B, E, and D β-strands of the host protein CD2.  
CD2.7E15 is also called EEDDD after the designed ligand residues at the sequential 
positions 15, 56, 58, 62, and 64 (the same nomenclature was used for its variants). 
CD2.7E15 has been chosen as an excellent template to investigate the effects of charge 
and ligand type on the Ca2+ binding based on following considerations. First, this metal 
binding site is well embedded on the protein frame, allowing for the study of the 
interrelationship of calcium binding affinity, protein stability, and local factors. We have 
previously shown that the cluster of five negatively charged residues at this location has 
not disrupted the folding of the protein and that the metal binding has not altered the 
global conformation of the protein (5). Second, the conformational sensitive locations at 
wild type residues E56 and D62 are remain unchanged and the mutations were made on 
the other three ligand residues. Third, a series of variants that have net charges from -5 to 
-2 at the site were then generated by replacing Asp or Glu by Asn or Gln with its 
derivative without a sidechain charge (Table 1). Variants with net charges of -1 or 0 have 
not been generated since they are not expected to exhibit significant Ca2+ binding.  
Fourth, the variants EEDDD and EEDDE as well as EEDDN and EEDDQ have the same 
number of charges in their binding pockets with only one methylene group size 
difference at the last ligand position (64) to allow us to reveal the contribution of ligand 
types.  
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2.2.1 Conformational analysis of the 7E15 variants 
  At 25 °C the s.4 and 2.5far-UV CD spectra for all of the variants show a single 
negative maximum at ~216 nm nearly identical to the wild type CD2, which is an 
indicator of β-sheet proteins. Moreover, the Trp fluorescence emission spectra of the 
variants have a single maximum at 327 nm, which is the same as CD2 (Figure 2.4)  . This 
suggests that the mutations have not altered the native folding arrangement. The metal 
ions alter neither the CD nor the Trp fluorescence spectra, suggesting the absence of 
global conformational changes upon the metal binding (Figs 2.4 and 2.5). 7E15 and the 
7E15 variants all have a mostly beta sheet structure nearly identical to that of CD2.D1.  
The secondary structural differences with and without metal are minimal, resulting in 
overlapping  far UVCD spectra for the metal free (1 mM EGTA) and calcium loaded 
forms (10 mM CaCl2).  According to Trp fluorescence spectra, the protein 7E15 and its 
variants do exhibit tertiary packing that is significantly different from wild-type CD2.D1 
with or without metal.   
2.2.2 FRET Metal Binding Studies of CD2.7E15 and its Variants 
The metal binding studies were done by Anna Wilkins Maniccia for her PhD 
dissertation (Georgia State University, Department of Chemistry, summer 2005).  .  
Taking advantage of the closely located aromatic residues in the host frame,Trp32 and 
Tyr76, metal binding of the 7E15 variants was investigated using aromatic sensitized 
fluorescent resonance energy transfer (FRET). The addition of the wild type CD2 into a 
Tb3+ solution caused a mildly 2-3 fold increase of the Tb3+ fluorescence emission at 545 
 20
nm due to the nonspecific interactions. On the contrary, the addition of EEDDD (7E15), 
EEDDE, EEDDN, and EEDDQ into the Tb3+ resulted in more than 30-fold increases in 
Tb3+ fluorescence emission. The addition of EENDN resulted in a smaller signal 
enhancement at the same protein concentration. The addition of NENDN only resulted in 
a slight enhancement that is comparable to the CD2, suggesting that the protein does not 
bind to Tb3+ or the binding affinity is very weak, which agrees with the prediction by the 
surface potential. The cited at 280 nmTb3+-binding affinities were obtained by directly 
titrating Tb3+ into protein (Table 1). The variants with -5 charges have the strongest Tb3+-
binding affinities of < 1 µM. The variants with -4 charges have Tb3+-binding affinities at 
µM level. The weaker binding of EENDN was not accurately measured due to the 
limitation of solubility that prohibits the usage of high Tb3+ concentration for this series 
of proteins. La3+ binding affinities were obtained by competitive titrating of La3+ into 
Tb3+-protein mixtures and monitoring the decrease in Tb3+ fluorescence intensity at 545 
nm. The trend of La3+-binding affinities for the 7E15 variants is the same as that for Tb3+, 
that is, the variants with a net charge of -5 show the strongest binding followed by the 
variants with a net charge of -4, -3 and -2. The addition of Ca2+ into Tb3+-protein mixture 
led to only small decrease in the Tb3+ fluorescence, suggesting the competition between 
Ca2+ and Tb3+ is inefficient and Ca2+-binding affinities are weak. Therefore, alternative 
method is required for the measurement of Ca2+-binding affinities. 
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2.2.3 Metal Titrations using NMR 
All metal titrations using NMR were done by Dr. Wei Yang.  The Ca2+-binding 
affinity of EEDDD has been determined to be 100 ± 50 µM from the chemical shift 
changes of the residues proximate to the metal binding position using 1H-15N HSQC 
spectra. Similar Ca2+ titrations have been performed on the other variants. Ca2+ 
specifically induced the movements of several resonances while the other resonances 
maintain the same positions through the whole titration process for the variants with -4 
and -5 charges. As an example, Fig. 5a shows the 1H-15N HSQC spectra of EEDDQ. 
Based on the original assignment of EEDDD, part of the resonances in the spectra of 
other variants has been identified. Several moved resonances are from the ligand residues 
or neighbouring residues including G61, L63, Q64, E58, E56, and K66 as well as Q22. 
The Ca2+-binding affinities of EEDDE, EEDDQ, and EEDDN were obtained by 
following the change of these residues. Unlike the Tb3+ and La3+ binding, EEDDQ with -
4 charges has a stronger Ca2+-binding affinity than EEDDE with -5 charges. In addition, 
the net chemical shift changes induced by Ca2+ binding for EEDDQ are greater than that 
for EEDDE. On the contrary, EENDN possesses minor but evident resonance movement 
at high Ca2+ concentration while NENDN does not undergo any significant changes with 
the addition of up to 13 mM Ca2+. This suggests that EENDN has a weak Ca2+ binding 
ability while NENDN does not have observed Ca2+ binding. Furthermore, the results 
confirmed that the chemical shift changes of the variants with higher negative charges are 
from the Ca2+ binding but not from other processes such as salt effects.  
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2.2.4 Charge effects on Ca2+ and Ln3+ binding affinities. 
The 7E15 variants with a net charge of -5 at the designed site have the strongest 
binding affinities for Tb3+ and La3+ followed by the variants with -4, -3, and -2 charges. 
However, for Ca2+ binding, a net charge of -5 is not always preferred compared to that of 
-4. The results correlate well with the previous experimental and theoretical studies that 
indicate that Ln3+ binding prefers a higher number of charged ligands compared to Ca2+ 
binding. Theoretical calculations from Lim and colleagues have shown that Ln3+ prefers -
5 charges while Ca2+ prefers -4 when the ligands have freedom to adjust the binding 
geometry. In addition, denser negative charges and buried environment favor Ca2+ 
displacement by La3+. Falke el al. have experimentally shown that mutating a Gln residue 
in the Ca2+-binding site of galactose binding protein to an acidic residues (D and E) or to 
a structurally similar residue (N) almost completely abolished Ca2+ binding while the 
Ln3+ show a slightly higher binding affinity. This is due to that trivalent Ln3+ binding is 
more efficient in compensating the increased repulsion of the charged side chains than 
divalent Ca2+ binding. The galactose binding protein has optimized size and charge in the 
coordination sphere for Ca2+. 
 The metal binding  sites in the 7E15 variants are on the surface of the proteins. 
Their binding geometry is not completely restricted and also not completely free to be 
adjusted. For Ln3+ binding, the effects of charge interaction are dominant. Thus, the La3+ 
and Tb3+ binding affinity decrease follows the trends of net negative charge decrease. 
However, for Ca2+ binding, contradicted results were obtained. The variant EEDDQ with 
-4 charges has higher Ca2+ affinity than EEDDE. It seems that a compromise between the 
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charge interaction and geometric arrangement is achieved. One more methylene group in 
the sidechains of EEDDE or EEDDQ provides additional freedom for the sites, making 
them more similar to the theoretical calculation that a net charge of -4 is preferred. On the 
other hand, the Ca2+-binding geometry of EEDDD and EEDDN is relatively restricted. 
As a result, the repulsion of the negative charges has less difference between the Ca2+-
loaded and Ca2+-free forms. Since the apparent binding affinity is dependent upon the 
energy difference between the Ca2+-loaded and Ca2+-free forms of the protein, the 
attraction introduced by the bound Ca2+ becomes the dominant factor and the higher 
charged sites possess stronger binding affinities. Therefore, the determinant for such 
higher Ca2+-binding affinity is the decreased stability at the Ca2+-free form of the protein 
instead of the increased stability at the Ca2+-bound form. The lowered thermal transition 
point of EEDDD supports this hypothesis. Overall, when the binding geometry or the 
charge distribution during the binding process is not restricted, Ca2+ prefers -4 charges. If 
the charge distribution is limited in a narrow region, denser charges might attract Ca2+ 
more strongly. It is noteworthy that in natural proteins a cluster of 4 or 5 negative charges 
often makes the protein in a different conformation or unfolding.  
2.2.5 Effects of Steric Size on Metal Binding binding   
The generally used ligand types to generate a Ca2+-binding site are D, E, N, and 
Q. A statistic study has shown that Asp is the most preferred ligand in naturally-evolved 
Ca2+ binding sites followed by Glu, Asn, and Gln. That is, charged ligands are preferred 
over non-charged ligands (D and E over N and Q) due to the charged nature of Ca2+ and 
shorter sidechains are preferred over longer ones (D and N over E and Q) due to 
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unknown reasons. However, in 7E15 variants, a short sidechain does not show advantage 
over a longer one. While EEDDD possesses a higher Ca2+ affinity than EEDDE, EEDDN 
possesses a lower affinity than EEDDQ. As mentioned previously, substitution of Gln 
with Asn in the galactose binding protein results in the Ca2+ binding affinity decrease. It 
looks like that as long as the Ca2+-binding pocket formed properly, the steric size of the 
ligand residues is less important for the Ca2+ binding. Thus, the less frequency for E and 
Q in naturally-evolved Ca2+-binding sites might be determined by factors other than the 
Ca2+ binding, such as the requirement of conformational changes or proper stability. In 
7E15 variants, the additional sidechain methylene group increases the thermal transition 
points both in the absence and presence of cations.  
2.2.6 Thermal Stability of CD2.7E15 and its Variants in the Apo-form  
The thermal transition points (Tm) of all variants were obtained using far-UV CD 
(Fig 2.6). 7E15 and its variants lose their native conformations at 90 ºC and the unfolded 
state resembles that of wild type CD2. CD2 has a melting temperature of 61 ± 1 ºC (51).  
The clustered negative charges at the β-strands decrease the thermal stability of EEDDD 
(41 ± 1 ºC) and EEDDE (45 ± 3 ºC) in the absence of metal. The -4 charged variants have 
higher Tm values of 53 ± 2 ºC for EEDDN and 56 ± ºC for EEDDQ under the same 
conditions. The EENDN (61 ± 1 ºC) and NENDN (62 ± 1 ºC) have similar Tm values 
with CD2 in the absence of metal (Fig 2.7).   Upon binding Ca2+ or Tb3+, the Tm values of 
-4 and –5 charged variants of 7E15 increase.  A ~10 ºC Tm increase was observed for 
EEDDD and EEDDE. A ~5 ºC increase of Tm was observed for EEDDN and EEDDQ. 
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For EENDN and NENDN with less charge at the binding site, the presence of Ca2+ or 
Tb3+ has not caused significant differences in the Tm values. As a result, although the 
trend of thermal transition points all following CD2 ~ NENDN ~ EENDN > EEDDQ > 
EEDDN > EEDDE > EEDDD both in the presence and absence of Ca2+ or Tb3+, the net 
difference is smaller in the presence of the cations.  
2.2.7 The Effect of Ligand Type and Net Charge on Thermal Stability 
Surface charge-charge relationships have been shown to play a major role in 
protein stability and may potentially be manipulated to increase protein thermal stability 
(52).  The effects of charged ligand residues on the stability of the proteins Table 2.2  the 
absence of Ca2+ with  gradually increased Tm values (Figure 2.7) versus the decreased net 
charges -5 to -2. The protein surface potential calculation also indicated a similar trend. 
The repulsion between the negative charges is obviously the determinant for such charge-
related thermal transition differences. In addition, it has been noticed that Tm values for 
EEDDD and EEDDN in the presence and absence of Ca2+ are lower than the 
corresponding Tm values for EEDDE and EEDDQ with the same net charges. It is likely 
that the additional methylene of Glu or Gln allows the sidechain oxygen atoms to rotate 
away from the others such that any charge interaction is reduced. The longer ligand may 
also allow increase in van der Waals interactions with nearby residues. This is different 
from the DelPhi calculation that shows EEDDE and EEDDQ have higher energy levels in 
the absence of cations. This difference is likely arisen from the fixed local conformations 
in the calculation, which assumes that the ligand sidechains retain similar positions 
among different variants as well as in the absence and presence of cations. Indeed, in 
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solution, the freedom provided by the additional sidechain length allows the protein to 
adopt a local conformation with a less charge density. 
Binding of Ln3+ or Ca2+ neutralizes the charge repulsions, resulting in the thermal 
transition point increase. More the charge clustered at the location, greater the effect of 
the cation binding. EEDDD and EEDDE underwent a Tm enhancement of ~10 °C and 
EEDDN and EEDDQ underwent a Tm enhancement of ~5 °C while the effect of Ca2+ or 
Tb3+ binding on the Tm of EENDN and NENDN is insignificant. Many proteins require 
Ca2+ for structural stabilization. For example, Ca2+ binding increased the thermal 
transition points of equine lysozyme or α-lactalbumin more than 45 °C (53).  The thermal 
transition point of Ca2+-loaded E-cadherin domains 1 and 2 is 25 °C higher than that of 
the apo-form (54).  The role of Ca2+ in stabilizing secondary and tertiary structures is not 
always reflected by dramatic conformational change (55). Similarly, 7E15 variants do not 
have significant secondary structural differences in the presence or absence of Ca2+  Ca2+ 
conferred thermostability (Table 2.2).  
2.2.8 Protein surface electrostatic potential.  
The electrostatic energy levels of proteins provide clues on the cation binding and 
stability of the proteins. For 7E15 variants, the relative Ln3+ and Ca2+ binding as well as 
the thermal stability from the electrostatic calculation and the experimental measurement 
agree each other at most cases. For example, the variants with more negative charges 
possess stronger Ln3+ affinities and lower thermal transition temperatures. The variants 
EENDN and NENDN do not bind to Ln3+ and Ca2+ or have very weak binding affinities. 
In the presence of divalent or trivalent cations, the thermal transition points increases and 
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the increasing level is related to the clustered charge numbers. However, the prediction is 
not completely consistent with the experiments, mainly for EEDDE and EEDDQ. The 
electrostatic potential is calculated based on the model structures and the residue atoms 
are assumed to be unmoved upon the cation binding. This is not true since at least local 
conformation rearrangement will occur upon the binding. Therefore, the energy 
difference between the cation-free and –loaded forms reflects more the relative strength 
of pure cation binding process but not including the energy cost for the conformational 
change. The higher Tm values for EEDDE and EEDDQ compared to EEDDD and 
EEDDN indicate that EEDDE and EEDDQ maintain relatively lower energy levels both 
with and without the cation binding. The results suggest that without the global 
conformational changes, longer sidechains facilitate the local geometric adjustment to 
stabilize the protein. In addition, the apparent Ca2+-binding affinity depends on the energy 
difference of the two forms of the protein. Thus, the effect of the longer sidechains on the 
affinity depends on the different effects on the apo- and loaded forms (56-59). 
2.3  Conclusions 
In summary, in a relatively restricted Ca2+-binding site, more negative charges 
facilitate the Ca2+ and Ln3+ binding accompanying with a tradeoff of protein stability due 
to the high energy level of the apo-forms. When the apo-form of the protein is capable of 
maintaining a relatively lower energy due to the global or local conformational change, a 
charge number of -4 is preferred for Ca2+ over -5 because at the Ca2+-loaded form the 
attraction between the Ca2+ and the fifth negative charge cannot compensate the repulsion 
of multiple negative charges. It looks like that the steric size of the ligand residues is not 
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crucial as long as the Ca2+-binding pocket is properly formed but the additional freedom 
of E/Q over D/N facilitates lowering the energy level of the protein. Ca2+ or Ln3+ binding 
increases the thermal transition temperatures relating to the clustered charge numbers at 
the site. The development of steadfast trends in Ca2+-conferred thermal stability and Ca2+ 
binding affinity in relation to net charge and ligand type would be beneficial. Using these 
trends, it may be feasible to develop mutant Ca2+-dependent thermozymes with enhanced 
stability. More importantly, a better understanding of the key factors involved in Ca2+ 
binding affinity and Ca2+-conferred thermal stability will aid in dissecting the role of 
aberrant Ca2+ binding proteins in diseases.  
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Figure 2.1 Design of Calcium binding protein CD2.7E15 
Left: pentagonal bipyramidal arrangement of the metal binding site.  Right: 
Molscript of CD2.7E15 based on the solution structure of CD2.D1 (PDB ID 1HNG) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2 pGEX-2T Expression and Purification SDS-PAGE 
SDS-PAGE of a CD2.7E15 variant expressed using a GST-fusion system (pGEX-2T 
vector).  Left: expression of a CD2.7E15 variant.  Lane 1 is before induction, lanes 2, 
3, and 4 are taken at one hour increments after induction with 0.4 mM IPTG.  
Right: Affinity column purification.  Lane 1 is the supernatant after sonication, 
lanes 2 and 3 are the Glutathione sepaharose beads after binding to the supernatant, 
lane 4 is the waste after binding, lanes 5 and 6 are the glutathione sepharose beads 
after cleavage with thrombin protease, and lane 7 contains the molecular weight 
standards.  
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Figure 2.3 pGEX-2T purification 
Top: size exclusion chromatograph.  Lower left: example of UV absorbance 
spectrum of purified protein.  Lower right: cation exchange chromatograph 
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Figure 2.4  Far UVCD analysis of CD2.7E15 and its variants  
Far ultraviolet circular dichroism spectra of CD2.D1, and the CD2.7E15 variants 
with and without calcium.  . 
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Figure 2.5  Trp Fluorescence Spectra of CD2.7E15 and its Variants 
Tryptophan fluorescence emission specra of CD2.D1, and the CD2.7E15 variants 
with and without calcium 
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Figure 2.6  Temperature Dependence of CD2.7E15 monitored by Far UVCD 
Left: Fractional change of far UVCD signal (in mdeg) at 225 nm with increasing 
temperature from 15 to 80 °C.  Right: far UVCD spectra of CD2.7E15.EEDDE in 
increasing temperature.  
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Table 2.2  Summary of Tm Values Observed using Far UVCD 
Melting temperatures (Tm) of CD2, CD2.7E15, and CD2.7E15 variants determined 
by fractional change of CD signal at 225 nm.  All experiments were done in 10 mM 
TRIS, 10 mM KCl plus 10 mM CaC2, 1 mM EGTA, or 50 uM Tb(III).   
58.2±3.660.2 ±2.857.7 ±1.2NENDN (-2)
58.7±1.861.3 ±1.559 ±1.1EENDN (-3)
53.7±0.551.9 ±1.556.7EEDDN (-4)
59.5±0.555.9 ±0.661.0 ±1.3EEDDQ (-4)
63.5±1.644.2 ±1.556.1EEDDE (-5)
---40.951.17E15/EEDDD
---68.2 ±1.364.3 ±2.5CD2
Tm Tb(III)Tm EGTATm Ca(II)Protein
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3 Increasing the Yield of 7E15 and 7E15-bom 
 The second objective of this work is to develop a simple, rapid, high-yield protein 
purification procedure for the engineered protein contrast agents (see detailed 
introduction in section 1.2).  This section describes the expression and purification 
experiments directed towards increasing the yield of purified CD2.7E15 and CD2.7E15-
bom beyond the levels previously attained using pGEX-2T vector and BL21 E. coli 
expression system (described in Chapter 2). 
3.1 Materials and Methods 
3.1.1 Cloning 
All cloning experiments were done by Lixia Wei (PhD candidate at the time of 
this thesis, Georgia State University Department of Biology).  The CD2.7E15 or 
CD2.7E15-bom sequence was removed from a pGEX-2T vector using BamH1 and 
EcoR1.  The 7E15 sequence was then ligated into the modified pET30a vector.  The 
pET30a vector was modified by removal of the S Tag and the 7E15 and 7E15-bombesin 
sequences were ligated into the modified pET30a vector using BamH1 and EcoR1.   
3.1.2 Transformation of E.Coli 
pGEX-2T vectors with ampicillin resistance (T7 promoter) were used for the 
cloning and site-directed mutagenesis.  Protein sequences were between BamH1 and 
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EcoR1 restriction sites.  The pGEX-2T vector allows for the expression of a Glutathione 
S-Transferase (GST) fusion protein with a thrombin protease cleavage site so that affinity 
column purification using agarose/glutathione beads can be used to capture the protein of 
interest and then remove the protein from the GST using thrombin.  The designed 
proteins can be cleaved from the GST in the column or in solution.    Transcription of the 
fusion protein sequence was controlled by the lac promoter so that expression could be 
induced at a desired time.   
 The heat shock technique was used to transform all E. coli.  To begin the 
procedure, a 1.5ml eppendorf tube containing approximately 100 uL desired competent 
cells (BL21 (DE3) for expression, DH5α for DNA purification) was obtained from a 
stock of competent kept at -80° C.  The cells were placed on ice to thaw and aliquotted 
into two 50 µL samples.  One sample receives 0.5-1.0 µl of desired plasmid DNA while 
the other did not receive DNA (this is the negative control).  The thawed cells and DNA 
were mixed by pipetting up and down or gently flicking the bottom of the tube.  The cells 
were left on ice for at least thirty minutes after the addition of DNA.  The heat shock was 
done by placing the cells in a 42 °C water bath for ninety seconds and then putting the 
cells back on ice for two minutes.  Then, 50 µL LB media was added and the media was 
mixed with the cells by pipetting up and down or by gently flicking the bottom of the 
eppendorf tube.  The tubes were then incubated at 37 °C for 30 minutes.  50 µL of the 
solution was added to desired agar plates (LB-Amp plates for expression) and streaked 
onto the plates with a sterile triangle.  The plates were then incubated at 37° C overnight.  
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The plates were wrapped in parafilm and placed upside-down in the refrigerator the 
subsequent morning.  No plates were kept longer than one month. 
3.1.3 Expression of Histidine Tagged CD2.7E15 and CD2.7E15-bomesin 
Lauria-Bertani broth was prepared according the recipe in the appendix.  A single 
colony from a transformed plate with the plasmid of the desired protein was inoculated 
into at least 100-500 ml of LB broth with an ampicillin concentration of 100 µg/ml for 
overnight growth at 37° C and 200-220rpm agitation.  The following morning, 30-100 ml 
of the overnight growth was transferred to 1L of fresh LB broth with a kanamycin 
concentration of 30 mg/L.  The flask was then incubated at the desired temperature and 
200-220 rpm agitation.  The growth of the cells was monitored by measuring the optical 
density (light scattering) at 600 nm and comparing to the optical density of LB before the 
addition of cells.  When the desired optical density was reached (0.8-1.0), the cells were 
induced with 0.2-1.0 mM IPTG.  Samples were taken during expression for analysis 
using SDS-PAGE.  The first sample was always taken immediately before induction with 
IPTG and subsequent samples were taken at various times during expression.  The cells 
were allowed to grow 2-4 hours after induction according to the progress of cell growth 
as indicated by optical density readings.  The cells were harvested by centrifugation in 
500 ml bottles at 7 krpm for 15-20 minutes using a GS3 rotor.  The cell pellets were 
collected using a spatula and less than 5 ml PBS buffer and placed in a 50 ml falcon tube 
and stored at -20 °C for purification at a later date. The supernatant was discarded. 
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3.1.4 Isolation of Inclusion Bodies Enriched with Insoluble Protein 
The desired cell pellet was thawed out on ice or in cold water.  20-50 ml 200 mM 
NaCl, 50 mM Tris, 1 mM EDTA, pH 8.0 per 2L culture pellet was added to re-suspend 
the cell pellet from expression.  First, the suspended cell pellet was homogenized in a 
commercial blender by blending 2-3 times for 30 seconds.  This solution was sonicated 6 
times for 90 seconds using a Branson 450 Sonifier with the duty cycle set on 90 with 5-
10 minutes between sonications.  The solutions were kept on ice during sonications.  The 
solutions were centrifuged in 50 ml tubes at 17 krpm for 20 minutes using the S34 rotor 
after sonications.   
After cell lysis and centrifugation, inclusion bodies were found in the cell pellet.  
The cell pellet also contains other insoluble impurities.  To remove the lipid-soluble 
impurities, cell pellets were resuspended in 1% Triton X-100 and re-centrifuged.  This 
procedure was repeated for 3-4 cycles before nondenaturing or denaturing solubilization. 
3.1.4.1 Solubilization in Arg 
 To solubilize inclusion bodies, 300 mg washed inclusion bodies was dissolved in 
10 mL 1 M Arg, 200 mM NaCl, 50 mM TRIS, 1 mM EDTA, pH 8.0 for 16 to 20 hours at 
4 degrees Celsius with agitation.  This protocol is modified from Umetsu et al, who used 
listed their arginine concentration as 2M (60).  Since arginine is not soluble at lower 
temperatures at 2 M, the concentration of arginine was reduced to 1 M for this study. 
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3.1.4.2 Solubilization in Urea for refolding 
To solubilize inclusion bodies under denaturing conditions, washed inclusion 
bodies were dissolved in 8 M Urea overnight at 4 °C with agitation.  Refolding was done 
by diluting the solubilized cell pellet in half with 50 mM TRIS, pH 8.0, or 20 % Sucrose, 
50 mM TRIS, pH 8.0.  Refolding volumes <1 mL were done using a microdialyzer kit 
and 3 kDa cellulose membranes.  First, the solubilzed protein was placed in the 
microdialyzer well and the well was covered with parafilm.  Next, the buffer 
compartment was filled with the desired buffer and placed at 4 °C on a magnetic stirring 
plate.  The buffer was changed after 1 hour, and again after 4 hours, then allowed to 
equilibrate overnight.  The proteins refolded at volumes >1 mL had to be placed in 
cellulose dialysis bags.  The bags were placed in 2 L desired buffer and placed at 4 °C on 
a magnetic stirring plate.  The buffer was changed after 1 hour, and again after 4 hours, 
then allowed to equilibrate overnight. 
3.1.5 Ni-sepharose affinity column chromatography 
Gravity-flow Ni-sepharose affinity chromatography was done by decanting 
solubilized protein in the denatured or refolded form into a Ni-Sepharose column 
provided by GE Healthcare.  Protein was eluted from the column using 0.5 M Imidazole.  
The column was provided by GE Healthcare. 
3.1.6 Size exclusion chromatography 
6-10 ml of crude protein was injected into a Pharmacia Biotech FPLC system.  
When the elution volume was greater than 20 ml the elution was concentrated using an 
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Amicon high pressure concentrating apparatus and an Amicon membrane filter before 
injection.  Samples are filtered with a 0.45 µm filter before injection.  Proteins were 
purified using a size exclusion column and the concentration of each fraction was 
measured using the UV absorbance (280 nm). The experimentally determined molar 
extinction coefficient for domain one of wild type CD2 was used for CD2.7E15 (11700 
M-1cm-1).  To determine the concentration of CD2.7E15.bom, the theoretical extinction 
coefficient (19630 M-1cm-1) calculated based on the primary sequence (available at 
http://www.basic.northwestern.edu/biotools/proteincalc.html)  was multiplied ratio 
obtained by taking the experimentally-determined extinction coefficient of CD2.d1 
divided by the theoretical value for CD2 ((11700 M-1cm-1)/ (13940 M-1cm-1)).  Fractions 
with a  A280/A260 ratio less than 1.0 were rejected, since this would indicate significant 
nucleic acid contamination. 
3.1.7 Cation exchange chromatography 
A 5 mL cation exchange column provided by Pharmacia Biotech was used for 
IEC.  Proteins were bound to the cation exchange column at pH 3.0-4.0 and eluted with a 
buffer gradient beginning at pH 4.5 and ending at pH 8.0.  The protein in the resulting 
fractions was collected according to the quantification procedure in section 1.1.6.  
Fractions with a A280/A260 ration less than 1.0 were rejected or subjected to further 
purification.  Addition of benzonase nuclease during the sonication procedure mad the 
incidence of a A280/A260 ration less than 1.0 a rare occurrence.   
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3.1.8 MALDI Linear Positive Mass Spectrometry 
 The purity of the protein was assessed using MALDI mass spectrometry.  The 
samples were scanned in a sinapinic matrix on an ABI Voyager-DE™ Pro Workstation 
(MALDI) in the linear positive mode.  All mass spectrometry samples were done in 50 
mM Tris, pH 8.0.  The samples were given to the Georgia State University’s 
Biotechnology Core Facility.  The samples were stored at 4 °C until analysis. 
3.1.9 Calculation of Protein Concentrations 
Protein concentrations were determined by measuring UV absorbance from 350 nm 
to 220 nm.  A minimum volume of 800 µL was used in a 1 cm quartz cell.  First, the 
Shimadzu spectropolarimeter was baselined from 350 nm to 220 nm using nanopure 
water.  Then, a blank was kept in the standard slot while the samples were measured in 
the sample slot.   
Because large particles scatter light, a high absorbance at 350 nm relative to 
absorbance at 280 nm (>about 10 % maximum absorbance at 280 nm) was taken to 
indicate precipitation.  When precipitation was detected or anticipated, samples were 10x 
diluted with buffer or scanned after the addition of 100 mM Arginine, pH 8.0.   
 To obtain the protein concentration, the absorbance at 350 nm was subtracted 
from the absorbance at 280 nm (which should be the absolute highest peak in the 
spectrum).  Then, Beer’s law was applied to calculate protein concentration using the 
relevant extinction coefficient (A=εcl).  The experimentally determined extinction 
coefficient for wild-type CD2.D1 is 11700 M-1 cm-1.  The extinction coefficient for 7E15 
and histidine-tagged 7E15 (pET30a vector) is taken to be identical to that of CD2.D1 
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because no aromatic residues have been added or replaced, and the tertiary structures are 
not significantly different (see Chapter’s 3 and 5).  The theoretical extinction coefficient 
for 7E15 based on the primary amino acid sequence is 13940 M-1 cm-1 and that of 7E15-
bombesin is 19630 M-1 cm-1.   
The theoretical extinction coefficient of 7E15-bom was corrected by dividing the 
experimentally determined extinction coefficient of 7E15 by the theoretical extinction 
coefficient to give 16500 M-1 cm-1.   
Thus the extinction coefficients used throughout this thesis are as follows:  
7E15, CD2, and his-7E15: 11700 M-1 cm-1 
7E15-bom:   16500 M-1 cm-1 
3.2 Results & Discussion 
3.2.1 Expression 
To optimize expression of histidine tagged CD2.7E15, we have varied 
temperature of expression and concentration of IPTG.  The expression of the contrast 
agent in the pET30a vector was found to require relatively high concentrations of IPTG 
to induce expression (1mM).  0.1 mM, 0.3 mM and 0.5 mM were unsuccessful at 
inducing any appreciable expression.  The protein could be detected using Western blot 
using an anti-CD2 antibody, but not on SDS-PAGE stained by coomasie blue (Fig 2.3.2).  
The expression at 1 mM IPTG was able to produce large amounts of protein, as 
evidenced by the sizeable expression band visible on SDS-PAGE (Fig 2.3.3). 
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To determine whether or not the high expression level of 1 mM IPTG induction 
could be utilized to yield soluble protein, the temperature of expression was changed to 
30 °C for 5 hours and 22 °C overnight (data not shown).  Both procedures resulted in 
inclusion body formation with CD2.7E15 absent from the supernatant after sonication, 
indicating that the variation in temperature had not affected the solubility of expressed 
protein. 
Overall, when 1 mM IPTG is used to induce expression at 37 °C, a very large 
expression band can be seen on coomasie blue stained SDS-PAGE at the appropriate 
molecular weight (see Fig 3.3).  The protein at this band reacts with anti-CD2 antibody in 
Western blot, confirming that it is the desired protein.  CD2.7E15-bom was also 
successfully expressed at 37 °C for four hours (expression data not shown).  The final 
expression band seen is very thick on SDS-PAGE, often thicker than that seen for pGEX-
2T expressed CD2.7E15, which is remarkable since the pET30a construct is much 
smaller than the GST-fusion protein produced by the pGEX2T vector. 
3.2.2 Purification  
 The purification of his- CD2.7E15-bom was initially attempted under denaturing 
conditions.  The inclusion bodies were solubilized in 8M urea and dialyzed against 10 
mM Tris, 10 mM KCl.  The dialysis produced a large mass of white precipitate.  After 
centrifuging the precipitate, soluble protein remained suspended.  This protein could be 
purified using cation exchange (Fig 3.5) for a yield of 6 mg/L cell culture, which already 
exceeds the yield provided by the GST fusion system (2mg/L cell culture of 7E15-bom).   
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The refolding of CD2.7E15-bom was attempted against 20% sucrose at low 
volumes (400-500 uL) and various concentrations.  The sucrose causes preferential 
hydration of proteins, which would thermodynamically favor the most compact structure 
(61).  In the case of globular proteins such as CD2 and its mutants, this is probably the 
native state.  The protein remained soluble in the 20 % sucrose and seemed to have a 
secondary structure similar to CD2.7E15 purified using the GST-fusion system, as 
evidenced by the mostly beta-sheet secondary structure (Fig 3.4).  However, this method 
was not suitable when the purification was scaled up to 1, 4, and 10 mL.  This may be 
due to the difference in dialysis procedure.  The lower volumes used a microdialysis 
system, where a single permeable membrane below the sample allows solvent exchange.  
The larger volumes required the protein sample to be placed in a dialysis bag, which 
allows solvent exchange from all directions.  This rapid removal of sugar may have 
destabilized the protein. 
 Nondenaturing solubilization as described by Umetsu et al (60) was found to be 
the best solubilization procedure; yielding an average of 20 ± 5 mg/ 300mg wet 
solubilized inclusion bodies for his- CD2.7E15.  Histidine-tagged CD2.7E15-bom did not 
solubilize well in the high arginine buffer (data not shown), which could be due to a lack 
of secondary or tertiary structure in the insoluble form.  Cell lysis using sonication results 
in a cell pellet that contains most of the desired protein for CD2.7E15 and CD2.7E15-
bom (Fig 3.7).  Washing in 1 % Triton X-100 probably removes lipid-soluble 
contaminants, which seems to relieve some of the smudging of SDS-PAGE (Fig 3.7).   
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The protein solubilized using 1 M arginine solution was exceptionally pure after 
size exclusion chromatography as visualized by SDS-PAGE (Fig 3.7).  The SDS-PAGE 
shows no impurities and the linear positive mode MALDI mass spectrum contains two 
major impurities at 10648, 15771 Da/ charge (Fig 3.8).  The arginine solubilization 
provides an initial enriching procedure because the CD2.7E15 is the main constituent of 
solubilized protein.  The protein of interest is sufficiently different in molecular mass 
from most of the other solubilized proteins to be purified using a G75 sepharose size-
exclusion chromatography column.   
 CD2.7E15-bom could not be solubilized in 1 M arginine, which may suggest that 
it is unfolded in inclusion bodies.  The protein was successfully solubilized in 8 M Urea 
and refolded using 20 % Sucrose (Fig 3.4).  The protein was unfolded in 8 M Urea as 
shown by the random coil far UVCD spectrum and became mostly beta sheet after 
dialysis against 20 % Sucrose, 50 mM Tris, 50 mM KCl, pH 8.0.  The protein did not 
acquire a secondary structure identical to 7E15 purified using the GST-fusion system 
because of the additional random coil character conferred by the histidine tag and the 
fourteen residue bombesin tag.  This refolding procedure was successful at volumes less 
than 1 mL, but did not scale up very well.  The proteins refolded using this protocol were 
subsequently purified using size exclusion chromatography before the far UVCD 
spectrum was taken (Fig 3.4). 
A simple solubilization using 8 M Urea and dialysis against 50 mM Tris, 50 mM 
KCl was attempted.  The solubilized inclusion bodies precipitated after dialysis.  The 
insoluble fraction was removed by centrifugation and the supernatant was purified using 
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cation exchange chromatography (Fig 3.5).  The yield of CD2.7E15 bom using this 
procedure was 6 mg/ L cell culture, which already exceeds the yield of CD2.7E15-bom 
using the GST-fusion system. 
The solubilized protein was also purified in denaturing conditions using a Ni-
sepharose column.  The resulting elution was pure, but it precipitated (Fig 3.5). 
Nondenaturing solubilization is superior to the refolding techniques explored in 
this chapter because it takes advantage of proteins that are already fully or partially 
folded rather than exposing the protein to denaturing conditions, from which it could 
potentially fail to recover.  The insoluble aggregates after arginine solubilization could be 
subjected to a refolding procedure in the future to develop a more efficient purification 
method.  The majority of the insoluble pellet is the desired protein and the majority of the 
protein solubilized by 1M Arginine is the desired protein.   
Solubilization at 4 ºC does not solubilize as much DNA: the ratio of 280 nm/260 
nm absorbance for 4 ºC solubilization was 1.25 compared to 1.13 for 27 °C and 1.02 for 
37 ºC (Fig 3.6).  Solubilized DNA can interfere with further purification using FPLC, as 
the peak monitor only detects absorbance at 280 nm which can come from the tail of a 
strong absorbance at 260 nm.  This may be a result of arginine’s reduction in protein 
thermal stability (62). 
3.2.3 MALDI Mass Spectrometry 
 The protein his- CD2.7E15 was analyzed using linear positive MALDI masss 
spectrometry.  The major m/z peak was found at 12356.4 Da.  The molecular weight of 
his-7E15 is 12356 Da by mass spectrometry, which is 1067 Da larger than CD2.7E15 
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purified using the GST fusion system, a result of eight residues at the N-terminal of 
CD2.7E15  (HHHHHHSSG) conferred by the pET30a vector (Fig 3.8).  This has to be 
considered when comparing the yields of his- CD2.7E15 and CD2.7E15 purified using 
the GST fusion system.  The addition of the histidine tag and its accompanying residues 
constitute a 10 % increase in molecular weight, which is insignificant given the massive 
increase in purification yield.   
3.3 Conclusions and Future Work 
Induction with 0.3 mM IPTG can produce expression levels detectable by Western 
blot with an Anti-CD2 antibody, but western blotting techniques are considerably more 
sensitive than coomassie blue stain (Fig 3.2).  For these studies, and, more importantly, 
the proposed application of CD2.7E15, a much higher expression level is needed. The 
pET30a vector requires induction with IPTG concentrations in excess of 0.5 mM, but the 
resulting expression level is high (Fig 3.3).   
The histidine-tagged CD2.7E15 protein can be purified using either refolding or 
nondenaturing solubilization.  Nondenaturing solubilization in 1 M Arg probably works 
by causing preferential hydration of the individual molecules that are fully folded, which 
would favor the most compact solution structure (63, 64).  The most compact structure of 
a globular protein like CD2 or CD2.7E15 is probably the native structure.  It is possible 
that this high concentration of arginine could cause partially folded intermediates that 
have been sequestered into inclusion bodies to adopt the compact native structure.  
According to the data presented here it is most likely that the arginine is releasing 
proteins from inclusion bodies that are already folded or sufficiently close to the compact 
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globular structure.  The solubilization buffer contains 200 mM NaCl, which may act to 
increase hydrophobic interactions such that unfolded proteins that have aggregated at 
hydrophobic contacts remain insoluble, while the arginine keeps the proteins that are 
folded in a compact state.  The selective solubilization of the overexpressed CD2.7E15 
can be seen in the SDS-PAGE (Fig 3.6).  The 8 M Urea solubilizes all constituents of the 
inclusion bodies, folded and unfolded, while the 1 M Arg buffer solubilizes only the 
proteins that were folded, which is predominantly the overexpressed protein of interest.  8 
M urea preferentially binds to proteins, causing indiscriminate solubilization and 
unfolding (65). 
Looking at solubilization in 4 °C, 27 °C, and 37 °C, There seems to be a 
temperature dependence of arginine solubilization with 4 °C providing the most protein 
solubilized.  This can be seen on SDS-PAGE and is in good agreement with the 
absorbance ratio between 280 nm and 260 nm—4 °C has the most protein solubilized and 
the highest ratio of protein to DNA solubilized (Fig 3.6). 
The overlapping Trp fluorescence spectra of CD2 and CD2.7E15 purified using 1 
M Arg solubilization is the strongest piece of evidence for a fully compact tertiary 
structural arrangement (Fig 4.1).  This is an important piece of information, as it goes 
against the classical method of purification from inclusion bodies.  This is also a shining 
example of the stability of CD2; it has managed to maintain its tertiary structure after 
three mutations have been made to produce a surface metal binding site, a 6 x histidine 
tag has been added to the N-terminal, and it has been sequestered in inclusion bodies.   
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In summary, the non-denaturing solubilization purification procedure developed 
in this section has exceeded the yield of CD2.7E15 purified using the GST-fusion system 
by taking advantage of inclusion body purification, selective nondenaturing solubilization 
of overexpressed protein, and subsequent purification using size exclusion 
chromatography.   
In the future, an additional or alternative purification step should be explored 
because the protein contains some impurities detected by linear positive MALDI mass 
spectrometry.  The first alternative purification method should be FPLC Ni-chelating 
column chromatography or gravity-flow Ni-Sepharose chromatography after arginine 
solubilization.  Also, perhaps solubilization in various concentrations of arginine, urea, 
and GdHCl can be compared to determine the optimal conditions of nondenaturing 
solubilization.   
Because a histidine tagged protein cannot be used in vivo, a thrombin cleavage 
site is included between the histidine tag and the protein.  This is also important because 
the histidine tag is probably affecting the solubility of CD2.7E15, which can normally be 
concentrated to 200 to 400 uM concentrations without excipients, while the histiding-
tagged protein purified in this thesis was found to require 0.1% polysorbate 20 to achieve 
approximately 200 uM concentration.   
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Figure 3.1  pGEX-2T Expresion and Purification SDS-PAGE 
SDS-PAGE analysis of expression and purification of CD2.7E15.  Lanes marked M 
are the protein standards of 66, 24, and 14 kDa.  Left: CD2.7E15 expression using 
pGEX-2T.  Lane 1 is the cells before induction with 0.3 mM IPTG and lanes 2, 3, 
and 4 are taken at 1 hour increments after induction.  Right: Glutathione-sepharose 
affinity column purification of CD2.7E15.  Lane 1 is the supernatant after 
sonication, 2 & 3: beads after binding, 4: waste after binding, 5 & 6: beads after 
thrombin cleavage, 7: elution after cleavage. 
 
 
 
 
 
 
 
Figure 3.2  Failed his-7E15 Expression and Purification SDS-PAGE 
A) SDS-PAGE of expression of his-7E15-bombesin in pET30a.  Lane 1 is 1 hour 
after induction with 0.4 mM IPTG, Lane 2 is 2 hours after and so on.  M contains 
the MW standards, which, from top to bottom, are 66, 24 and 14 kDa.  B)  Lane 1 is 
Ni-NTA fraction 5, Lane 2 is a dilution of Ni-NTA fraction 6, Lane 3 is fraction 6 
from the Ni-NTA column, Lane 4 is 7E15 purified using a GST-tag, lane 5 is SEC 
fraction 9, lane 6 is SEC fraction 10, and lane 7 is all other SEC fractions.  The 
protein marker is in the lane marked “M.” C) Western blot using an anti-CD2 
monoclonal antibody.  The lanes are, from left to right: 7E15 purified using the 
GST-system (lane 4 in figure 2B); 7E15-bom-his (lane 5 in figure 2B); 7E15-bom-his 
( lane 6 in figure 2B); and 7E15-bom-his ( lane 7 in figure 2B).                    
1      2      3      4      M        M   1     2     3    4    5     6    7
C)
17 kDa
B)
1       2       3      M 4       5     6       7 
1         2         3        4        M
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Figure 3.3  Successful pET30a Expression Growth Curve and SDS-PAGE 
Left: Expression of CD2.7E15 using a pET30a vector in BL21 cells monitored by 
optical density at 600 nm.  Right: SDS-PAGE analysis of CD2.7E15 expression.  M: 
protein standards 66, 24, and 14 kDa, 1-4: 1 hour increments after induction with 
1.0 mM IPTG, 5-7: before induction. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4  Refolding of his-7E15-bom in Sucrose 
Left: SDS-PAGE analysis of CD2.7E15 (lanes 1-3) and CD2.7E15.bom (lanes 4-7) 
refolded against 20% sucrose solution and then purified using size exclusion 
chromatography.   M is the protein molecular weight standards of 66, 24, and 14 
kDa.  Right: Far ultraviolet circular dichroism spectra of CD2.7E15.bom unfolded 
and refolded in 20 % sucrose compared to 7E15 purified using the GST-fusion 
system (10 mM TRIS, pH 8.0). 
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Figure 3.5  Purification SDS-PAGE 
SDS-PAGE analysis of CD2.7E15 each gel contains MW standards of 66, 24, and 14 
kDa.  Left: IB’s solubilized in 8 M and the SN after dialysis.  Center: Fractions after 
CEC purification.  Right: the left lane is the waste after Ni-Sepharose purification 
and the right lane is the elution. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6  Arg Solubilization Temperature Dependence 
Left: SDS-PAGE analysis of CD2.7E15 solubilized in 1 M arginine and 8 M Urea.  
Center: Ratio between UV absorbance of IBs solubilized at different temperatures.  
Right: CD2.7E15 solubilized at 4, 27, and 37 degrees Celsius.  The markers for each 
SDS-PAGE gels are 66, 24, and 14 kDa.  
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Figure 3.7  Arginine Solubilization and SEC Purification  
SDS-PAGE analysis of CD2.7E15 purified using Arginine solubilization and size 
exclusion chromatography.  Left: Solubilization procedure.  1: supernatant after 
sonication, 2: supernatant after washing with 1% Triton X-100, 3: cell pellet after 
sonication, 4: supernatant after solubilization with 1 M Arginine, 5: cell pellet after 
washing, 6: cell pellet after solubilization and centrifugation. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8 Linear positive mode MALDI mass spectrometry analysis of CD2.7E15 
purified using 1 M Arginine solubilization and size exclusion chromatography. 
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4 Preparation and Physical Properties of Microspheres Consisting of Albumin 
Encapsulated Contrast Agents  
Albumin microspheres are micrometer-sized capsules consisting of an albumin 
scaffold in which drug molecules may be immobilized.  The albumin molecules are 
crosslinked with glutaraldehyde, with the degree of crosslinking determining the time 
required for the albumin matrix to disperse and release the loaded drug (see figure 4.1).  
Albumin encapsulation has the following applications in optimal drug delivery: sustained 
or timed release, prolonged circulation time, targeted delivery, high-capacity drug 
delivery, non-immunogenicity, and protection from proteases. 
Due to the selective portioning of micrometer-sized particles, albumin 
encapsulation will provide our contrast agent with  a prolonged circulation time and 
targeted delivery (43).  Microspheres shift the Biodistribution to the vasculature by 
increasing circulation time and selective phagocytosis by endothelial cells (32, 66-68).  
Haswani, et al found that 46% of free gentamicin accumulated in endothelial cells, while 
86% of encapsulated gentamicin was found in endothelial cells.  Also, selective 
phagocytosis of albumin microspheres by lung-associated lymphatic tissues has been 
observed.  Finally, and perhaps most relevant to this thesis project, the interstitium of 
tumors and inflamed tissues receive large amounts of injected microspheres due to 
enhanced capillary permeability (34-37).      
The high capacity of albumin microspheres (up to 10 to 20 % drug by weight) is a 
major advantage due to the concentration dependence of contrast-enhanced MR imaging.  
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The scaffold molecule, bovine serum albumin (BSA), is nonimmunogenic and protects 
encapsulated products from proteases (38-40, 69).   
The glutaraldehyde crosslinking process creates a covalent linkage between free 
amino groups (either lysine or N-terminal) in the BSA so that BSA polymers are created.   
The degree of BSA crosslinking can be manipulated to cause microspheres to release 
their contents slower (sustained release) or after a certain period of suspension (timed 
release).  In the future, microspheres containing our designed protein contrast agents 
could be formulated such that dissolution is timed to occur when microspheres have 
partitioned to tumors. 
The goal of microsphere encapsulation of the contrast agents, 7E15 and 7E15-
bombesin, is to provide a scaffold for tumor-specific drug delivery, while shielding from 
circulating protease activity.  Although not discussed in this thesis, the possibility of 
vascular and pulmonary imaging, and the optimization of release kinetics, will be 
explored in the future.   
  The spray drying of albumin microspheres was performed by Neil J. Patel at 
Mercer University’s Department of Pharmaceutical Science in Dr. Martin D’Souza’s 
laboratory (see figure 4.2 for a diagram of a laboratory scale spray dryer). 
4.1 Materials and Methods 
4.1.1 Sample Preparation and Spray Drying  
The BSA formula is patented by Dr. Martin J. D’Souza’s group at Mercer 
University’s Department of Pharmaceutical Science.  To prepare a sample for spray 
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drying, protein contrast agents were combined with the BSA formula according to the 
desired drug/BSA ratio.  The initial formulation is a liquid, with BSA at 5 mg/mL.  7E15-
bombesin loading ranged from 1-10% by final composition of microspheres.  The 
histidine tagged CD2.7E15 and CD2.7E15-bom could be concentrated to >200 µM using 
0.1 % Polysorbate 20 in 50 mM TRIS, pH 7.4.   A solution of 475 mg BSA was 
combined with 25 mg of CD2.7E15, CD2.7E15-bom or Gd-DTPA for 5 % loaded 
microspheres.  For those microspheres containing stabilizing trehalose, a solution of 450 
mg BSA, 25 mg trehalose, and 25 mg of CD2.7E15, CD2.7E15-bom or Gd-DTPA was 
used.  The 2 % crosslinked microspheres were produced by reacting the BSA solution 
with glutaraldehyde and then stopping the crosslinking reaction before adding CD2.7E15, 
CD2.7E15-bom or Gd-DTPA.For those samples containing Gadolinium, the protein was 
incubated with 1:1 GdCl3 (molar ratio) for >2 hrs before being combined with the BSA 
solution for spray drying.  Before spray drying loaded microspheres, a blank sample was 
always prepared to check the machinery.  Low yields would have required that 
adjustments be made until a suitable yield could be obtained using only BSA and the 
excipients (typically defined as >75 %).   
All samples were spray-dried on Büchi B191 Laboratory Scale Spray Dryer in 
Mercer University’s Department of Pharmaceutical Science.  A homogenous mixture of 
MRI contrast agent: trehalose: BSA (1:1:18) was dissolved in citrate buffer, pH 6.0 so as 
to make a 5% solution was prepared for spray drying.  Spray drying was performed using 
a laboratory scale spray dryer (Buchi B-191), which operates in co-current flow.  This 
model uses co-current air flow so that the hottest air contacts the coolest liquid.  A 
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pneumatic two-fluid pressure nozzle with a 0.7 mm diameter was used to atomize the 
homogenous solution.  The nozzle was supported by a peristaltic pump rate of 5% and an 
in-house supply of compressed air at 700 NL/hr.  The filtered air was aspirated at 75%.    
The inlet and outlet temperatures were 110˚C and 63˚C respectively.  The solvent from 
the droplets of homogenous solution were evaporated by hot air during its descent within 
the spray cylinder, thereby forming solid microparticles.  The solid microparticles were 
further processed by separation through a High Efficiency Performance Cyclone and 
ultimately settled and collected in a 30 dram glass vial.  The vial was parafilmed upon 
completion of spray drying and stored at 4 °C. 
4.1.2 Laser Particle Size Measurements 
The size of the spray-dried microspheres was determined using a Spectrex IR 
Laser particle sizer, which measures the Rayleigh scattering of focused infrared light to 
determine particle sizes.  Sizes greater than 10 micrometers or less than 1 micrometer 
cannot be discerned.  Spray dried microspheres were simply dissolved in filtered sterile 
water and scanned (the exact concentration is not necessary).  The Spectrex IR Laser 
particle sizer software averages all particle sizes together and provides a standard 
deviation.  It will also give a particle count and categorize each particle according to 
micrometer size (using whole numbers up to 10).  The values in Table 3.1 are the average 
of n=3 with standard deviations.  The proteins marked “his-“ were purified using the 
arginine solubilization or sucrose refolding procedures outlined in Chapter 1 of this 
thesis.  The blank microspheres are microspheres consisting of albumin only.  The 
protein that isn’t marked “his-“ was purified using the GST-fusion system.   
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4.1.3 Zeta Potential Determination 
Equation 1 
 
 
 
 
 
Zeta potential measurements were done on a Malvern Zetasizer.  The zeta 
potential is a measurement of the ion cloud surrounding a particle.  Low zeta potentials 
indicate particles that need to be reformulated because they would tend to aggregate, 
preventing dissolution.  This analysis is crucial for microspheres—particles with a low 
zeta potential should not be used in vivo because they would aggregate possibly causing a 
stroke or other ischemia. 
To measure zeta potential, microspheres were dissolved in filtered 1 M KCl and 
the dissolved mixture was used to fill an electrophoretic cuvette provided by the 
manufacturer (Malvern) (approximately 1 mL is needed).  An electrical field of known 
strength was applied, through which a laser is then passed. The electrophoretic mobility 
of the colloid dictates the velocity of the movement of charged particles.  The zetasizer 
measures frequency shifts in an incident laser beam.  Using the equation above, the zeta 
potential of the particles within the colloid can be calculated (see equation 1). 
=Electrophoretic mobility
=Dielectric constant
=Zeta potential
=Henry’s function (1 or 1.5)
=viscosity
Ue
ε
Ζ
f(ka)
η
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4.1.4 MALDI Linear Positive Mass Spectrometry 
Mass spectrometry measurements were taken according to the same specifications 
given in section 2.2.3. 
4.1.5 Measuring Protein Concentration 
Please see section 2.1.8 for a detailed description.   
4.2 Results & Discussion 
The designed protein contrast agents were successfully spray-dried.  The zeta 
potential measurements are shown in (Table 3.2).  The zeta potential measures the 
relative stability of a colloid.  The ion cloud surrounding a particle must be of a sufficient 
strength to counteract Van Der Waals force between particles.  If it isn’t large enough, 
the particles will aggregate.  It is not possible to dictate an exact threshold of zeta 
potential that is ideal without knowing the magnitude of Van der Waals attraction 
between particles, but a zeta potential that is small in magnitude does suggest a particle 
with a tendency to aggregate.  The particles with the lowest zeta potential were not the 
particles that were found to be the largest in the diameter measurements by Rayleigh 
scattering (Table 4.3), which suggests that perhaps the zeta potential is large enough in 
magnitude to prevent a significant aggregation of the particles.    
There is a range of microsphere sizes produced by the methods described in this 
chapter.  The optimal size range for passive targeting to tumor, pulmonary, or other 
vascular beds must be experimentally determined.  The microsphere size is affected by 
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The initial sample volume and the spray nozzle diameter.  Slight variations in sample 
volume may have resulted in aberrations in particle size.   
The mass spectrum of the blank microsphere shows that the blank microsphere 
contains BSA only (represented by several m/z peaks in Fig 3.3.3).  Any contaminants 
significant enough to be detected by MALDI mass spectrometry could affect the outcome 
of subsequent experiments.  The CD2.7E15 microspheres contain only CD2.7E15 and 
BSA (see Fig 4.3).   
4.3 Conclusion 
The microsphere preparation process produces microspheres of a range of sizes.  At 
this stage, the goal was merely to prepare albumin encapsulated formulations of the 
designed protein contrast agents and determine whether or not spray drying had a 
significant deleterious effect on the metal binding or relaxivity.  The manipulations 
necessary to produce particles of uniform size shall be done in the future when the 
optimal size to suit our purpose is determined experimentally through in vivo studies.  
The changes in formulation necessary to determine optimal size will likely be concurrent 
with studies aimed toward determining the best crosslinking percentage to facilitate 
passive targeting.  Each new formulation will require new zeta potential measurements.   
 In summary, CD2.7E15 has been spray dried with and without equimolar 
gadolinium, CD2.7E15-bom has been spray dried with gadolinium, Gd-DTPA has been 
spray dried, and CD2.7E15 purified using the pGEX-2T expression and purification 
system has been spray dried with and without gadolinium.   
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Figure 4.1  SEM of Albumin Microspheres and the Crosslinking Reaction  
Top: Scanning electron micrograph of albumin microspheres.  This micrograph is 
of microspheres that do not contain any drugs (http://www.alrise.de/images/great-
microspheres.jpg).  Bottom: mechanism of glutaraldehyde crosslinking 
(http://www.lsbu.ac.uk/biology/enzyme/images/practi11.gif). 
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Figure 4.2  Diagram of a laboratory scale spray dryer. 
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Table 4.1  Size Distribution of Microspheres 
Size distribution of microspheres measured by Spectrex Laser Particle Counter 
(n=3).  The proteins marked his- were purified using the solubilization protocol 
developed in this thesis.  The other was purified using the GST fusion system (see 
chapter 1).   
3.17 ± 0.8
(3-4 µm range)
7E15+Gd
6.85 ± 0.8
(5-9 µm range)
His-7E15-bom+Gd
3.21 ± 0.5
(3-5 µm range)
His-7E15 no Gd
4.41 ± 0.6
(3-7 µm range)
His-7E15+Gd
5.72 ± 0.5
(5-7 µm range)
“empty” µsphere
4.93 ± 0.5
(4-6 µm range) 
“empty” µsphere
Size (µm)Contrast agent
µsphere
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Table 4.2  Zeta Potential Measurements 
Charge distribution of microspheres measured by a Malvern Zetasizer (n=3).  The 
proteins marked his- were purified using the solubilization protocol developed in 
this thesis (chapter 2).  The other was purified using the GST fusion system (see 
chapter 1).   
-27.6 ± 0.37E15+Gd
-35.9 ±1.2His-7E15-
bom+Gd
-16.9 ±3.8His-7E15 no Gd
-26.9 ±2.9His-7E15+Gd
-11.6 ±0.9“empty”
µsphere
-31.8 ± 0.8“empty”
µsphere
Charge
(mV)
Contrast agent
µsphere
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Figure 4.3  Linear positive MALDI mass spectra of blank microspheres (top) and 
CD2.7E15 microspheres loaded with Gd(III).   
The tertiary structure of CD2.7E15 is a molscript construction based on wild-type 
CD2.D1.  The tertiary structure of BSA is a crystal structure (www.wikipedia.com)
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5 Biophysical characterization of contrast agents before & after encapsulation 
5.1 Materials and Methods 
5.1.1 Separation of his-7E15-bom from microspheres 
 The histidine tag was utilized to purify spray-dried protein.  Microspheres 
dissolved in 50 mM Tris, pH 8.0 were decanted into a gravity-flow Ni-sepharose column 
to separate them.  The microspheres were dissolved in 20 mM Imidazole, pH 8.0.  
Histidine-tagged protein was eluted with 500 mM Imidazole, pH 8.0.  The resulting 
fractions were dialyzed against 10 mM Tris, 0.1% Tween 20, pH 8.0 to remove imidazole 
salt.   
 Alternatively, 25 mg spray dried albumin microspheres was dissolved in 11 mL 
50 mM Tris, pH 8.0 for two hours to allow complete dissolution (this was done on 
uncrosslinked microspheres, which dissolve and release their contents very easily).  After 
the required timeframe, 10 mL of the dissolved microsphere mixture was injected into a 
G200 Sephadex size exclusion column (G75 cannot be used; it does not resolve BSA) 
with the mobile phase as 10 mM Tris, pH 7.4. 
5.1.2 Far Ultraviolet Circular Dichroism 
 Far UVCD was performed on a Jasco 810 Spectropolarimeter.  In this section, 
protein concentrations were approximately 20 uM (0.2-0.25 mg/ml).  A 50 nm/min scan 
speed was used with 6 or more accumulations per measurement.  The response time was 
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2 seconds.  The data pitch was 1 nm.  All measurements were taken at room temperature 
(approximately 27 °C).   
5.1.3 Trp Fluorescence 
 Trp fluorescence was used to determine the tertiary packing of the proteins before 
and after spray-drying.  A 282 nm excitation was used and the emission of tryptophan 
was monitored from 300 to 400 nm.  The relative fluorescence is given by finding the 
maximum emission and finding the minimum emission (in counts per second).  The 
minimum is set at zero and the maximum is set at 1 by taking each point as x and using 
the following equation 
Equation 2 Normalizing fluorescence data 
(x –min emission)/(max emission –min emission)=normalized fluorescence 
After normalization, a more accurate assessment of tertiary structural differences can be 
made because identical spectra will overlap regardless of concentration differences. 
5.1.4 Tb-enhancement Resonance energy transfer  
Trp residues were excited at 282 nm.  The emission was monitored from 500 to 
600nm.  The baseline was normalized by deriving an exponential equation from the 
regions between 565-575 nm and 525-535 nm.  The fluorescence enhancement was 
monitored at 545nm with a glass plate between the protein sample and the emission 
detector to prevent Raleigh scattering.  The metal binding affinities were obtained by 
plotting the enhancement at 545 nm versus the total terbium concentration.  The resulting 
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plot was fitted using the hill equation (equation 3; the data could not be fitted with a 
single site equation.  The reasoning is discussed in the Discussion and the Conclusion). 
 
Equation 3  Calculating Metal Binding Affinity (multiple sites) 
 (m1*m4*(m0^m6/(m5^m6+m0^m6)));  
m4= maximum enhancement at 545 nm 
m5= protein concentration (5 µM) 
m6= metal binding sites (2) 
There were two different methods used to obtain a metal binding curve.  The first 
used direct, stepwise addition of a high [Tb (III)] solution to a protein solution with 5-10 
minutes between each addition.  The second used separate samples for each [Tb (III)] 
with the metal added and incubated for 3 hours before a Tb(III) emission spectrum was 
taken.   
5.1.5 Relaxivity measurements using NMR & MRI 
To determine the potential for use of 7E15-bom purified using the protocol 
described in Chapter 1 as a protein contrast agent, its relaxivity was measured before and 
after the spray drying and encapsulation process.  Relaxivity measurements were 
performed on 300 & 500 MHz NMR specrometers (GSU) and on 1.5, 3.0, and 9.4 Tesla 
MRI scanners (Emory U).   
5.2 Results & Discussion 
5.2.1 Far Ultraviolet Circular Dichroism 
 The contrast agent, his-7E15 was purified according to the Arginine solubilization 
procedure outlined in Chapter 1.  7E15 has a negative maximum of 216 nm in the 
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presence and absence of calcium or its lanthanide analogs and maintains its secondary 
structure over a wide range of pH values (from 3-10).  His-7E15 was tested to determine 
if the new construct has lost any stability or secondary structure.   
The far UVCD spectra of his-7E15 at pH 8.0 with and without metal are shown in 
figure 5.1.  The protein maintains a similar secondary structure in both conditions, but 
this secondary deviates from that of CD2, 7E15 and the 7E15 variants (see Chapter 2).  
This is not unexpected, since the his-7E15 construct has an additional nine residues that 
most likely do not adopt the beta sheet arrangement.   
The protein secondary structure does not change from pH 8 to pH 6 when metal is 
bound (figure 5.1B), but the protein precipitates at pH 4.5 causing a loss of total molar 
ellipticity and a change in the far UVCD spectrum (the precipitate here was visible during 
the experiment).   
The spectral changes observed with changing pH in the absence of metal are less 
dramatic, but they do provide information on the solubility of the his-tagged CD2.7E15 
protein.  The far UVCD measurements are all taken with the same protein concentration, 
so changes in mdeg intensity (molar ellipticity) can indicate precipitation.  The intensity 
with metal added is higher than the intensity without metal (figure 5.2.1 B and C), 
suggesting a loss of solubility.  The spectra of his-7E15 with and without metal at pH 6.0 
are highly similar, suggesting that the protein precipitates at this pH regardless of 
stabilization by metal binding.  To determine whether or not a protein could be spray-
dried and separated from the albumin matrix, an IgG was spray-dried according to the 
established protocol.  The IgG was successfully separated from the albumin matrix using 
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size exclusion chromatography and subsequently analyzed using ELISA (done by 
collaborators at Mercer University) and far ultraviolet circular dichroism spectroscopy.  
The BSA maintains a mostly alpha helical conformation, as evidenced by the deep trough 
from 208 to 222nm (Fig 5.7).  The IgG, however, has experienced some slight changes in 
secondary structure (Fig 5.7).  The significance of these changes has yet to be 
investigated.   
5.2.2 Trp Fluorescence 
The tryptophan emission maximum of his-7E15 overlaps with the emission 
maximum of 7E15 and wild-type CD2, suggesting that they all maintain a highly similar 
tertiary packing.  The tertiary packing does not change with the addition of 100 uM 
Tb(III).  which is 20 times the protein concentration in these measurements.  The large 
excess of Tb(III) should saturate the metal binding pockets.  The fact that there is no 
tertiary structural change with the addition of metal suggests that the protein does not 
show a global conformational change when binding metal. 
5.2.3 Tb (III)-enhancement Resonance energy transfer 
 The terbium fluorescence increases with increasing concentration, indicating a 
binding event (figure 4.2A).  The Tb (III) binding constant could not be determined.  
There is only one designed metal binding site in his-7E15 (figure 5.2C).  The 
fluorescence enhancement profile is consistent with two possibilities—either there is 
cooperative binding (often seen in proteins with 2 or more sites) or the metal binding 
causes a change in the structure of his-7E15.  The large error seen in the average 
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observed enhancement seems to suggest an alternative explanation.  Perhaps the binding 
is so strong for other metals (e.g. calcium or magnesium) that Tb (III) must be at a high 
concentration to compete with the other metals and cause displacement.  This can be 
alleviated by pretreating the buffers and protein samples with chelating reagents. 
5.2.4 Relaxivity measurements using NMR & MRI 
Table 5.1  Table Relaxivity measurements using 500 MHz NMR (approximately 
11.7 T).  All samples are measured in 10 mM TRIS buffer, pH 8.0.   
 
 
 
 
 
 
 
 
 The relaxivity measurements using 500 MHz NMR show that Gd-DTPA has a 
R1relaxivity of  5.3 mM-1 s-1, which closely correlates with the literature value of  5.0 
mM-1 s-1 measured using clinical MRI scanners (70).  This indicates that R1 relaxivity 
measurements using a 500 MHz NMR may provide a good prediction of relaxivity 
detected by a clinical MRI scanner.  The most encouraging piece of information gleaned 
from this experiment is that the R1 relaxivity of CD2.7E15 (referred to in the table as his-
7E15) does not change significantly after spray drying and encapsulation in albumin 
microspheres (his-7E15-Gd-µS).  The average R1 before spray drying is 4.75 ± 0.75 and 
• Varian Inova 500 MHz NMR, All samples in 10 mM Tris buffer, pH 8.0
50.32044.1188150his-7E15-Gd- µS
50.21354.71259100his-7E15-Gd-µS
187.6854.0190250his-7E15-Gd
246.4375.51141100his-7E15-Gd
R2 
(mM-1s-1)
T2
(ms)
R1 
(mM-1s-1)
T1
(ms)
[CA-Gd] 
(µM)
Contrast agent
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the average R1 after spray drying and encapsulation in albumin microspheres is 4.4 ± 0.3.  
The two values are within error, suggesting little to no change in R1 relaxivity (see table 
4.1).   
Table 5.2 Relaxivity measurements using a 3 T clinical MRI scanner.  Measurements 
provide by Dr. Hui Mao at Emory University Hospital  
 
 
 
 
 
 
 
 
 
 
The relaxivity of 7E15 does not exceed that of Gd-DTPA in this experiment.   
One thing to consider is that this magnetic field strength is very high (roughly 11.4 T), 
and R1 relaxivity is sensitive to changes in magnetic field strength.  This magnetic field 
strength is not FDA approved.  3 T, however has been approved, and measurements have 
been taken at this magnetic field strength.   
The results of relaxivity measurements on a 3 Tesla MRI at Emory University are 
shown in table 4.2.  The relaxivity measurements indicate that 7E15 generally has a 
higher relaxivity than Gd-DTPA in serum and PBS buffer.  Most importantly, Gd-7E15 
Table Relaxivity Measurements 3 T MRI scanner
19.0366100Gd-DTPA: Serum
16.1611.250Gd-DTPA: PBS
13.8452.5100Gd-DTPA: PBS
24.7483.950Gd-7E15-bom: PBS
20.8343.2100Gd-7E15-bom: PBS
21.0530.950Gd-7E15-bom: Tris
18.2377100Gd-7E15-bom: Tris
52.7288.550Gd-7E15-bom: Serum
31.3252.2100Gd-7E15-bom: Serum
R1 
(mM-1s-1)
T1
(ms)
[Gd(III)]
(µM)
Microsphere 
Sample: buffer
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microspheres in serum have a relaxivity that is more than twice as high as Gd-DTPA 
microspheres in serum.   
5.3 Conclusion  
According to the far UVCD data, the secondary structure of his-7E15 is different 
from that of 7E15.  Moreover, the protein becomes less soluble in low pH buffer and is 
generally less soluble without metal.  This may relate to the results of the initial metal 
binding titration, which seems to indicate a cooperative change (Fig. 4.3.2).  
 The titrations in Fig 5.2 show that no enhancement is seen in the lower Tb (III) 
concentrations.  This could indicate a cooperative binding event, where the Tb (III) 
binding event must first cause a change in the CD2.7E15 structure before energy transfer 
from tryptophan residues is observed.  A second possibility is that the metal binding is so 
strong that the protein has already accepted a metal from the buffer into its metal binding 
pocket, and that metal must be outcompeted by increasing Tb (III) concentrations before 
energy transfer can be seen.  
Both CD2.7E15 and CD2.7E15-bom were found to bind Tb(III) and the estimated  
Tb(III) Kd for CD2.7E15 is 3.5 ± 0.5 µM in 20 mM PIPES, pH 6.8.  This Kd was 
determined by preparing separate samples for each Tb (III) concentration and incubating 
them with the metal for three hours so that any residual metals that may have occupied 
the metal binding sites would be outcompeted by the Tb (III).    The energy transfer still 
shows little to know change in the lower Tb (III) concentrations, indicating that a more 
stringent means of metal removal should be employed for future titrations.   
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The 7E15 purified using the GST-fusion system and the CD2.7E15 purified using 
the system developed in this thesis have nearly identical maximum Tb (III) binding 
capabilities (Fig 5.4).  The maximum energy transfer is not significantly reduced by the 
addition of 130 mM NaCl, indicating that a specific binding event is responsible for the 
vast majority of the energy transfer.  Compared to CD2.7E15 purified using either GST-
fusion or the arginine solubilization procedure, neither CD2.D1 nor Bovine serum 
albumin did not have a significant energy transfer with or without 130 mM NaCl. 
  Interestingly, there is a reduction in maximal enhancement between the 7E15 
before spray drying and an equimolar solution of 7E15 in dissolved albumin 
microspheres, indicating that there may be some reduction in maximal metal binding.  
Nonetheless, the albumin encapsulated microspheres spray dried without gadolinium 
showed a very high FRET enhancement at 545 nm.  In fact, the energy transfer increased 
when 130 mM NaCl was used in the buffer.  This indicates that when nonspecific binding 
is minimized (e.g. that of BSA), the CD2.7E15 can bind more of the available 100 µM Tb 
(III) (Fig 5.4).  If there was no BSA present in the solution, the enhancement would 
probably increase—even the “blank” microspheres (those containing no CD2.7E15 or 
any protein other than BSA) have a high enhancement at 545 nm.  The spray-dried 
CD2.7E15 should be purified from the microspheres in the future so that this experiment 
can be repeated.    
As described in chapter 3, a simple, high yield purification procedure has been 
developed for CD2.7E15.  The protein shows a fully formed tertiary structure, but the 
secondary structure does not exactly overlap with that of 7E15 purified using the GST 
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fusion system.  This should be explored by further attempts at optimizing folding of the 
protein solubilized from inclusion bodies.  One technique that should be explored is the 
use of high pressure to facilitate folding, which, in combination with nondenaturing 
concentrations of GdmHCl has been shown to facilitate solubilization and refolding of 
growth hormone, lysozyme, and beta-lactamase (71).  This procedure allows for high 
concentrations to be refolded, abrogating the need for a concentrating step in the 
purification.  In chapter 4, the preparation of albumin encapsulated protein contrast 
agents was described, showing that the protein can be successfully spray-dried into 
micron sized particles of high quality.  Chapter 5 shows that the spray-dried protein 
contrast agents have a relaxivity that does not change significantly after spray drying.   
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Figure 5.1  Conformational Analysis of his-tagged CD2.7E15 before Spray-drying 
A) the tryptophan fluorescence emission spectra of his-7E15, 7E15 and wild-type 
CD2 with and without metal in 20 mM PIPES, pH 6.8.  B) The far UVCD spectra of 
his 7E15 in various buffers with 50 uM Gd(III) 1:50 mM NaAc, pH 4.5, 2: 50 mM 
PIPES, pH 6.8, 3: 20 mM Tris, pH 8.0.  C) The far UVCD spectra of his-7E15 in 
various buffers treated with 1 mM EGTA 1:50 mM NaAc, pH 4.5, 2: 50 mM PIPES, 
pH 6.8, 3: 20 mM Tris, pH 8.0.  D)  The far UVCD spectra of his-7E15 with 100 uM 
Tb(III) (1) and with 1 mM EGTA (2).   
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Figure 5.2  CD2.7E15 Metal binding studies 
A) Tb(III) FRET with increasing concentrations of metal in uM (legend).  B)  
Average enhancement profile of his-7E15 in 20 mM PIPES, 50 mM KCl, 2 uM 
protein.  C)  Rasmol model structure of 7E15.  The potential metal residues are 
shown in red and the tryptophan residues are shown in gold.  The metal is colored 
in green and is shown in the designed metal binding pocket.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Average enhancement @ 545 nm
-100000
0
100000
200000
300000
400000
500000
600000
700000
800000
900000
0 5 10 15 20 25 30
[Tb(III)] total
 (c
ou
nt
s 
x 
se
c
-1
)
B)
 (c
ou
nt
s 
x 
se
c
-1
)
0
1 105
2 105
3 105
4 105
5 105
6 105
500 520 540 560 580 600
0
0.312
0.623
0.93
1.24
1.55
2.17
2.78
3.39
4.601
6.987
9.326
11.9
14.71
17.44
21.69
25.78
co
un
ts
 x
 s
-1
Wavelength (nm)
[Tb3+]
A)
co
un
ts
 x
 s
-1
C)
 78
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3  CD2.7E15 Metal Binding Studies II 
Tb(III) titration using increasing Tb(III) concentrations.  Rather than increasing 
the Tb concentration in a single sample, separate samples were prepared for each 
concentration and incubated for 3 hrs. to allow sufficient metal binding.   The 
average of two measurements gives an estimated Tb(III) Kd for CD2.7E15 equaling 
3.5 ± 0.5 uM 
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Figure 5.4  Total Enhancement Assay 
Maximum energy transfer measured by enhancement at 545 nm in 20 mM PIPES, 
100 µM Tb(III) with and without 130 mM NaCl. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5  Total Enhancement Assay: Microspheres  
Comparison between the total FRET enhancement at 545 nm (Tb(III) emission) 20 
mM PIPES, pH 6.8 with and without 130 mM NaCl.  His-7E15 is at 5 uM, the 
microspheres are each 1mg/mL, roughly corresponding to a final concentration of 5 
uM 7E15.   
0
2 105
4 105
6 105
8 105
1 106
1.2 106
1.4 106
his-7E15 + 100 uM Tb(III)
his-7E15 + 100 uM Tb(III) + 130 mM NaCl
blank usphere + 100 uM Tb(III)
blank usphere + 100 uM Tb(III) + 130 mM NaCl
7E15 usphere + 100 uM Tb(III)
7E15 usphere + 100 uM Tb(III) + 130 mM NaCl
co
un
ts
 x
 s
ec
-1
2.0 x 106
1.6 x 106
1.2 x 106
8.0 x 105
4.0 x 105
0
C
ou
nt
s 
x 
se
c-
1 
@
 5
45
 n
m
hi
s
hi
s --
7E
15
7E
15
hi
s
hi
s --
7E
15
 
7E
15
 +1
30
 m
M
N
aC
l
W
t C
D2
.D
1
W
t C
D2
.D
1 +
13
0 
m
M
N
aC
l
W
t C
D2
.D
1
W
t C
D2
.D
1
BS
A
BS
A
7E
15
7E
15
7E
15
 
7E
15
 +1
30
 m
M
N
a
C
l
BS
A
 
BS
A
 +1
30
 m
M
N
a
C
l
C
ou
nt
s 
x 
se
c-
1 
@
 5
45
 n
m
hi
s
hi
s --
7E
15
7E
15
hi
s
hi
s --
7E
15
 
7E
15
 +1
30
 m
M
N
aC
l
W
t C
D2
.D
1
W
t C
D2
.D
1 +
13
0 
m
M
N
aC
l
W
t C
D2
.D
1
W
t C
D2
.D
1
BS
A
BS
A
7E
15
7E
15
7E
15
 
7E
15
 +1
30
 m
M
N
a
C
l
BS
A
 
BS
A
 +1
30
 m
M
N
a
C
l Exc: 282 nm
Em: 545 nm
 80
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6  Size exclusion purification of spray-dried commercial IgG.   
Top: G75 SEC Bottom: G200 SEC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.7  Spray-Dried IgG Far UVCD 
Far UVCD spectra of an IgG (left)  
and BSA(right) before and after spray-drying.  
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Table 5.3 Relaxivity Measurements on a 0.47 Tesla Relaxometer (Ga Tech) 
The measurements are of microspheres prepared at Mercer University spray dried 
without gadolinium.  Equimolar gadolinium was added after dissolution in 10 mM 
Tris, pH 8.0. 
 
9.17.3824135050507E15 µsphere-Gd
xx82913420507E15 µsphere-Gd
7.96.686814175050Blank µsphere-Gd
xx13222673050Blank µsphere
5.95.789314815050His-7E15µs-Gd
xx12122566050His-7E15µsphere
4.01.989918171000Gd-DTPA
xx1407278000(10mM)Tris
R2R1T2T1
Gd 
(uM)
Protein
(uM)Sample
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6 Introduction to Part II: β2-microglobulin as a Prostate Cancer Biomarker for 
Signal Transduction Studies 
Beta-2-microglobulin (β2m) is a structural constituent of the major 
histocompatibility complex I (MHC I), which is found on the surface of nearly all human 
somatic cells (72).  It is thought to contribute to the selection of MHC I associated 
peptide fragments (73, 74).  The structure of this 100 amino acid protein is similar to IgG 
light chains.  In 2006, Huang, et al found that β2m stimulates the proliferation and 
osteomimicry of prostate cancer bone metastases (75).  Use of an anti-β2m polyclonal 
antibody actually inhibited these effects, in some cases causing the bone metastases to 
atrophy (75, 76).  Studies have shown that the most efficacious antibodies bind to the 
MHC I complex, are internalized and activate Lyn and PLC gamma 2 which in turn 
activates JNK and inhibits PI3K/Akt and ERK inducing apoptosis (in myeloma cells) 
(76).  It has been suggested that the most potent antibodies have a higher affinity for 
MHC I-bound β2m.  The third major objective of this thesis is to determine the nature of 
this anti-tumor effect.  Since the antibody binding site is not known, our strategy involves 
identifying the epitope for the antibody that exhibited the inhibitory effects and producing 
a complementary peptide that can interfere with β2m signaling.  Our collaborators will 
determine the manner of β2m signaling while our lab will focus on the protein chemistry, 
which involves expression and purification of β2m and the synthesis of β2m peptide 
fragments.  Several epitope prediction algorithms were used to determine the regions of 
high antigenicity (77-79). 
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6.1 Expression and purification of rβ2microglobulin 
A pGFP plasmid containing B2m was obtained from our collaborators at Emory 
U (75, 80).  It was found that the expression level of this plasmid in BL21 was below the 
detection limit of SDS-PAGE, yielding a very poor purification (Fig 6.1).  A second 
vector, called pET-Blue2, was obtained from Dr. Andrew Miranker (Yale U).  This 
chapter details the expression and purification of protein obtained from this expression 
system.   
Histag pulldown assays are often used to determine determine the putative 
binding partner(s) of known proteins.  The known protein is expressed with a histidine 
tag so that when it binds to its partner(s) in vivo or in vitro, the entire complex can be 
precipitated using insoluble beads conjugated to a nickel atom chelated by a small 
organic molecule (e.g.: NTA).   
The pETBlue2 plasmid obtained from Dr. Andrew Miranker was superior to the 
pGFP plasmid; however, the B2m was inserted in the cloning region of pETBlue2 such 
that there is no histag.  
6.2 Materials & Methods 
6.2.1 Transformation protocols: DH5- and BL21 (DE3) competent cells 
The heat shock technique was used to transform all E. coli.  To begin the 
procedure, a 1.5ml eppendorf tube containing approximately 100 uL desired competent 
cells (BL21 (DE3) for expression, DH5α for DNA purification) was obtained from a 
stock of competent kept at -80° C.  The cells were placed on ice to thaw and aliquotted 
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into two 50 µL samples.  One sample receives 0.5-1.0 µl of desired plasmid DNA while 
the other did not receive DNA (this is the negative control).  The thawed cells and DNA 
were mixed by pipetting up and down or gently flicking the bottom of the tube.  The cells 
were left on ice for at least thirty minutes after the addition of DNA.  The heat shock was 
done by placing the cells in a 42 °C water bath for ninety seconds and then putting the 
cells back on ice for two minutes.  Then, 50 µL LB media was added and the media was 
mixed with the cells by pipetting up and down or by gently flicking the bottom of the 
eppendorf tube.  The tubes were then incubated at 37 °C for 30 minutes.  50 µL of the 
solution was added to desired agar plates (LB-Amp plates for expression) and streaked 
onto the plates with a sterile triangle.  The plates were then incubated at 37° C overnight.  
The plates were wrapped in parafilm and placed upside-down in the refrigerator the 
subsequent morning.  No plates were kept longer than one month. 
6.2.2 Transformation protocols:Tuner (DE3) pLacI competent cells 
Tuner (DE3) pLacI competent cells were obtained from Novagen and transformed 
as follows.  The desired quantity of cells (20 uL per transformation) was thawed on ice 
and mixed gently to ensure that cells were evenly suspended.  100-200ng DNA was 
directly pipetted into the thawed cells followed by trituration to ensure all DNA was 
released into the suspension.  Then the tubes were inverted to allow further mixing.  The 
cells were placed back on ice for 5 minutes before heat shocking for 30 seconds in a 42 
°C water bath.  Afterwards, the cells were placed back on ice for 2 minutes.  Finally, 80 
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uL of room temperature SOC medium was added to each tube and the entire mixture was 
plated onto LB-Ampicillin agar plates.   
6.2.3 Expression 
Lauria-Bertani broth was prepared using a single colony from a transformed plate 
with the plasmid of the desired protein was inoculated into at least 100-500 ml of LB 
broth with an ampicillin concentration of 100 µg/ml for overnight growth at 37° C and 
200-220rpm agitation.  The following morning, 30-100 ml of the overnight growth was 
transferred to 1L of fresh LB broth with an ampicillin concentration of 100 µg/ml.  If 
kanamycin was used as the selective antibiotic, as in pET30a expression, the final 
concentration used was 30 mg/L.  The flask was then incubated at the desired 
temperature and 200-220 rpm agitation.  The growth of the cells was monitored by 
measuring the optical density at 600 nm with fresh LB as a reference.  The cells were 
induced with 1 mM IPTG when the desired optical density was reached (0.8-1.0).  The 
cells were allowed to grow 4 hours after induction.  The cells were harvested by 
centrifugation in 500 ml bottles at 7 krpm for 15-20 minutes using a GS3 rotor.  The cell 
pellets were collected using a spatula and less than 5 ml PBS buffer and placed in a 50 ml 
falcon tube and stored at -20 °C for purification at a later date. The supernatant was 
discarded. 
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6.2.4 Purification scheme 
6.2.4.1 Solubilization in Arg 
See section 3.1.3 for a detailed protocol.  The only difference was that 2 M 
Arginine was used for beta-2-microglobulin solubilization according to Umetsu, et al 
(60). 
6.2.4.2 Size exclusion chromatography 
Size exclusion chromatography was performed on 10 mL solubilized beta-2-
microglobulin inclusion bodies.  The protocol was identical to the protocol used in 
section 3.1 of this thesis.  
6.2.4.3 Cation exchange chromatography 
Cation exchange chromatography was performed on the SEC fractions containing 
beta-2-microglobulin.  The protocol for cation exchange chromatography was identical to 
the protocol followed in section 1.1 of this thesis.  The concentration of the fractions 
obtained after cation exchange chromatography was calculated using a theoretical 
extinction coefficient from Expasyweb.com (19300 M-1 cm-1) and the calculated 
molecular weight  
6.2.5 Primer design 
The pGFP plasmid was obtained from Dr. Wen Chin Huang and Dr. Leland 
Chung at Emory University’s Winship Cancer Institute.  The restriction enzymes were 
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obtained from New England Biolabs and the KOD Hotstart Polymerase kits were 
obtained from 
The forward primer was designed to match the C terminal of the beta-2-
microglobulin sequence (obtained using a pET-Blue2 primer, sequenced at the Georgia 
State University Biology DNA Core Facility).  The forward primer has the following 
sequence: 
CAT CAT CAT CAT CAT CAT TAA AAG CTT GCG GCC GCA CAG 
The reverse primer was designed complimentary to the pET-Blue2 vector sequence 
immediately following the beta-2-microglobulin stop codon.  The reverse primer has the 
following sequence: 
CAT GTC TCG ATC CCA CTT AAC 
The stock solution of both the forward and reverse primers was 50 micromolar. 
6.3 Transformation of DH5-α , JM109, BL21, and Tuner(DE3) Competent Cells 
after PCR 
The competent cells were all transformed according to the protocol given in 
section 2.1.2 and section 8.1.2 of this thesis. 
6.4 Results & Discussion 
6.4.1 pGFP- rβ2microglobulin 
The pGFP vector and BL21 (DE3) E.coli were unsuitable for expression and 
purification of recombinant beta-2-microglobulin using a range of IPTG concentrations 
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(Fig 6.1).  This prompted the search for various other vectors.  The first expression 
system attempted was pET-Blue2 vector and Tuner (DE3) pLacI cells.  
6.4.2 pET-Blue2: Tuner DE3 system 
The Tuner (DE3) E. coli and pET-Blue2 vector produced a substantial expression 
band visible on SDS-PAGE (Fig 6.2).  The protein was completely insoluble after 
sonication and centrifugation, so the protein was purified using arginine resolubilization 
(see section 3.2 for a detailed protocol).  The beta-2-microglobulin has been successfully 
expressed and purified.  The resulting purification yields were 24 ± 2 mg per purification 
procedure.  Since each purification procedure uses only about ½ of a liter of cell culture, 
the yield is about 50 mg per liter of cell culture using this purification procedure.  
Unfortunately, our collaborators wish to use the purified protein for a histidine-tag pull 
down assay, so this purified protein cannot be used.  The protein must have a histidine 
tag, so PCR was attempted to insert a histidine tag at the C terminal of beta-2-
microglobulin in the pET-Blue2 vector.  
6.4.3 Cloning 
PCR products were successfully obtained using Green Master Mix reaction 
system.  The result of the KOD Hotstart Polymerase system shows a much lower yield 
than the Green Master Mix system.  In fact, the band on the Agarose gel may be simply 
template DNA (Figs 6.4 and 6.5).  Additionally, the lower forward and reverse primer 
concentrations resulted in a higher produce yield. 
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The PCR consistently showed a good yield, but the transformation step proved 
problematic.  The transformation step after the PCR failed using the DH5-α , JM109, 
BL21, and Tuner(DE3) competent cells. 
6.5 Conclusions and Future Work 
The beta-2-microglobulin construct within the pGFP vector cannot be expressed in 
BL21.  Successful expression and purification requires the pETBlue2 vector and Tuner 
(DE3) pLacI E.coli competent cells.  Unfortunately, this protein cannot be used for the 
proposed work using a his-tag pulldown assay.  An alternative approach would be to use 
an immunoprecipitation employing an anti-beta-2-microglobulin antibody.    
 The cloning results suggest that the final ligation step is faulty, as this would 
result in a linear plasmid that may not confer antibiotic resistance, causing the 
transformation using selective media to fail.   
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Figure 6.1  Beta-2-microglobulin pGFP vector SDS-PAGE analysis 
SDS-PAGE analysis of  beta-2-microglobulin expression in pGFP vector (bottom).  
Western blots were performed using anti beta-2-microglobulin antibody (top) and 
an anti-histidine tag antibody (center)[performed by Wen Chin Huang at Emory 
University  Winship Cancer Ins.]
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Figure 6.2  Beta-2-microglobulin pET-Blue2 Growth Curve and SDS-PAGE 
Successful expression of beta-2-microglobulin in pETBlue2 vector and Tuner (DE3) 
pLacI BL21 cells.  Theleft shows SDS-PAGE of expression.  The right is the optical 
density measurements of cell culture monitored at 600 nm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3  Beta-2-microglobulin Purification  
Left: SDS-PAGE analysis of beta-2-microglobulin solubilized in 2M Arginine, 200 
mM NaCl, 50 mM TRIS, pH 8.0 at 4, 27, 37, and 42 °C.  Right: SDS-PAGE analysis 
of beta-2-microglobulin purified by cation exchange chromatography.  
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Figure 6.4  pEt-Blue 2 Vector Map 
The beta-2-microglobulin was found to be inserted between the BamH1 and the 
HindIII enzyme cleavage sites. 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.5  Agarose Gel of PCR Result using KOD Hotstart Polymerase kit. 
The Green Master Mix system was used in the three left lanes, and the KOD 
Hotstart Polymerase system was used in the three right lanes.   
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7 Appendix I: Expression of a Single Chain anti-HER-2 antibody 
The HER-2 receptor is a member of the human epidermal growth factor receptor 
family.  This protein is also known as the avian erythroblastosis oncogene 2 (ErbB2), and 
the neuroglioblastoma (Neu) receptor.    Overexpression of this receptor is associated 
with decreased survival and increased recurrence (81-87).  Unfortunately, HER-2 is 
overexpressed in 20-40% of mammary carcinomas (72, 84, 86, 88, 89). 
Dimerization is required for activation of all human epidermal growth factor 
receptors (HERs) and all human HER isoforms are activated by binding to epidermal 
growth factor (EGF), which changes the conformation of the receptor to the dimerization-
competent form (85).  HER-2 overexpression is dangerous because all HER isoforms 
seem to prefer HER-2 as their dimerizion partner and the HER is permanently locked in 
the peptide-bound, dimerization-competent conformation.  Additionally, HER-2 
activation requires only that the HER-2 concentration be sufficiently high (90).  Finally, 
HER-2 overexpression correlates with resistance to tamoxifen, which is one of the most 
popular anti-breast cancer therapeutics today (85).   
There are many monoclonal antibodies directed against this receptor, the most 
well-known of these is trastuzumab (Hercpetin), which is used to inhibit the function of 
this receptor.  We have obtained a single chain antibody (ScFv), which is much smaller 
than an actual antibody (27 kDa vs >100 kDa).  Our goal is to conjugate this anti-HER-2 
ScFv to our protein contrast agent, 7E15, to use MRI to detect HER-2 overexpressing 
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tumors and metastases.  Efforts toward the expression and purification of the anti-HER-2-
ScFv will be outlined in this chapter. 
7.1 Materials & Methods 
7.1.1 Transformation 
The anti-HER-2 construct was contained within pCYN-B vector (T7 promoter).  This 
vector codes for the beta-lactamase gene for selective plating on Ampicillin or 
carbenicillin plates.   
The heat shock technique and elecrtroshock techniques were not necessary when 
using TG1 cells (ZYMO research).  To transform these cells, only 100 ng DNA was 
incubated with 50 uL cells on ice for 2 to 5 minutes.  Then, the entire mixture was spread 
onto a pre-warmed LB-agar plate (according to manufacturer’s instructions).   
When using BL21 or DH5-alpha competent cells, heat shock technique was needed.  
To begin the procedure, a 1.5ml eppendorf tube containing approximately 100 uL desired 
competent cells (BL21 (DE3) for expression, DH5α for DNA purification) was obtained 
from a stock of competent kept at -80° C.  The cells were placed on ice to thaw and 
aliquotted into two 50 µL samples.  One sample receives 0.5-1.0 µl of desired plasmid 
DNA while the other did not receive DNA (this is the negative control).  The thawed 
cells and DNA were mixed by pipetting up and down or gently flicking the bottom of the 
tube.  The cells were left on ice for at least thirty minutes after the addition of DNA.  The 
heat shock was done by placing the cells in a 42 °C water bath for ninety seconds and 
then putting the cells back on ice for two minutes.  Then, 50 µL LB media was added and 
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the media was mixed with the cells by pipetting up and down or by gently flicking the 
bottom of the eppendorf tube.  The tubes were then incubated at 37 °C for 30 minutes.  
50 µL of the solution was added to desired agar plates (LB-Amp plates for expression) 
and streaked onto the plates with a sterile triangle.  The plates were then incubated at 37° 
C overnight.  The following morning, the plates were wrapped in parafilm and placed 
upside-down in the refrigerator to retard drying of the agar gel.  No plates were kept 
longer than one month. 
7.1.2 Expression 
A single colony was inoculated into 500 mL LB media containing 100 mg/L 
ampicillin.  The colony was allowed to grow overnight at 37 °C and 180 to 220 rpm 
agitation.  50 to 100 mL overnight culture was inoculated into 1 L fresh LB medium (100 
mg/L ampicillin).  Expression at 37 C was monitored by measuring the light scattering of 
the media (O.D.600nm).  When the O.D.600nm= 0.8 to 1.0, 1 mL of 1 M IPTG solution was 
added to the growth to induce protein expression.  After three to five hours of expression, 
the cells were harvested by in 500 ml bottles at 7 krpm for 15-20 minutes using a GS3 
rotor.  The cell pellets were collected using a spatula and less than 5 ml PBS buffer and 
placed in a 50 ml falcon tube and stored at -20 °C for purification at a later date. The 
supernatant was discarded. 
7.1.3 Purification 
The desired cell pellet was thawed out on ice or in cold water.  50 ml 1X PBS, 0.1 
% Sarcosine, 1 mM EDTA buffer per 2L culture pellet was added to re-suspend the cell 
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pellet from expression.  First, the suspended cell pellet was homogenized in a commercial 
blender by blending 2-3 times for 30 seconds.  This solution was sonicated 6 times for 90 
seconds using a Branson 450 Sonifier with the duty cycle set on 90 with 5-10 minutes 
between sonications.  The solutions were kept on ice during sonications.  The solutions 
were centrifuged in 50 ml tubes at 17 krpm for 20 minutes using the S34 rotor after 
sonications.  The supernatant was purified using Ni-NTA Affinity Column Purification 
Ni-NTA Affinity Column Purification (FPLC) 
 The Ni-NTA affinity column purification was performed identically to the manner 
described in section 
7.1.3.1 Gravity Flow Ni-Sepharose Affinity column purification 
 
7.2 Results & Discussion 
Transformation of BL21 (DE3) and DH5-α could yield sparse colonies after 
transformation.  TG1 cells grew much stronger.   In both BL21 (DE3) and TG1 cells, 
expression of the anti-HER-2 ScFv was not detectable by SDS-PAGE (Fig 10.1).  Not 
surprisingly, the purification did not yield an appreciable amount of protein.   
7.3 Conclusion 
 The anti-HER-2 ScFv was not successfully expressed.  This may be due to a 
codon bias or the presence of disulfide bonds in the ScFv.   
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8 Appendix II: The Biodistribution of Protein Drugs 
8.1 Introduction 
Therapeutic use of proteins first gained popularity in the early 1900s when 
researchers first began to isolate purified peptide hormones from animals.  Bovine growth 
hormone was purified from the pituitary gland of beef cattle for the treatment of 
dwarfism (91).  While bovine growth hormone was found to be inactive in humans, other 
hormones proved clinically effective.  For example, calcitonin purified from salmon (and 
teleosts in general) is more active in humans than the human calcitonin (92).  The most 
successful early protein pharmaceutical was probably insulin purified from canine and 
porcine pancreatic homogenates (93).  The Novo Insulinlaboratorium (now Novo 
Nordisk, inc.) and Eli Lilly were major players in the initial stages of protein 
pharmaceutical development.  Both companies invested heavily in the isolation of insulin 
from canine and bovine pancreatic islets.   
For decades the production and discovery of protein pharmaceuticals was limited 
to proteins that occur naturally.  Today’s most powerful protein pharmaceuticals, 
antibodies, were useless in the clinical arena until relatively recent years.  Antibodies 
from nonhuman species are certain to elicit an immune response upon prolonged or 
repeated exposure.  It is difficult to purify antibodies from human blood and unethical to 
purposefully expose humans to antigens for the sake of antibody production.  The current 
expansion in the number of protein and peptide pharmaceuticals is due to the genomics 
revolution which began with the discovery of restriction enzymes in 1978 (94, 95) (96) 
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(97).  Antibodies and other peptides can now be humanized to avoid an adverse immune 
response.  Also, classical peptide pharmaceuticals such as insulin, human growth 
hormone, and luteinizing hormone releasing hormone can be mutated to manipulate 
circulation time or receptor affinity.  Finally, and perhaps most importantly, current 
technology allows various overexpression systems to simplify the production and 
purification of these recombinant proteins.   
In describing the in vivo behavior of a pharmaceutical, “biodistribution” is the 
terminology commonly favored by non-clinical research scientists.  This word usually 
describes the ultimate fate of an agent in a multicellular organism.    “Pharmacokinetics” 
is a much more descriptive word favored by clinicians and clinical researchers.  
Pharmacology deals with the absorption, distribution, metabolism, and excretion of 
drugs.  Each of these issues will be detailed in this review Drugs are designed to have an 
effect on the body and pharmacokinetics/Biodistribution describes what the body does to 
the drug.  .   
The distribution of any drug is based on the specific and nonspecific interactions 
at the molecular level.  Protein-protein interactions are dictated by size, charge, 
functional groups, and hydrophobic constraints.  In order for a protein drug to interact 
with another molecule, it must obviously come into close proximity.  The fate of a 
protein drug is first dictated by circulation and tissue penetration constraints, and 
ultimately by molecular interactions.  Thus, the principles of tissue perfusion provide the 
outline for this review.   
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Many protein drugs must retain a specific tertiary structure to remain biologically 
active.  Oral administration would inevitably lead to denaturation by the rapid pH 
changes associated with the digestive system and proteolysis by gastric pepsin or 
pancreatic enzymes.  Hence, protein drugs are largely limited to intravenous and 
intramuscular injections (blood or interstitium).  A few exceptions are on the horizon, 
such as inhalable recombinant growth hormone, calcitonin,  and monoclonal antibodies 
(98, 99), but a detailed discussion of these topics is beyond the scope of this review.  This 
review will focus more on the pharmacokinetics of protein pharmaceuticals as a result of 
molecular characteristics rather than routes of administration, formulation, or packaging.   
8.2 Circulation and tissue penetration 
  
The majority of drugs are intended for ingestion and absorption across the 
intestinal or stomach wall.  Generally, this route of administration is not feasible for 
protein and peptide pharmaceuticals.  Proteins typically rely on tertiary structure to 
maintain their ability to specifically interact with a target molecule.  Ingestion of proteins 
Table 8.1: Tissue Perfusion and O2 Consumption 
 
Organ Blood Flow 
Rate 
ml/min/100 g 
O2 Consumption/ 
O2 Delivery (%) 
Brain 54 34 
Heart 87 65 
Skel. Musc. 2.7 34 
Liver 58 18 
Kidney 420 8 
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would probably lead to unfolding in the low pH environment of the stomach.  The 
digestive enzymes of the stomach (pepsin) and duodenum (pancreatic enzymes and brush 
border carboxy- and aminopeptidases) would undoubtedly cleave most peptides.   Nearly 
all protein therapeutic agents are intended to be injected intramuscularly or intravenously.  
Intramuscular injections simply provide a reservoir for proteins to slowly enter the 
bloodstream; therefore, the circulation is the major determinant for the distribution 
component of pharmacokinetics.  The brain, liver, heart, and kidney are the most well 
perfused organs (see Table 10.1).  In addition to circulation to these organs, diffuse and 
ordered lymphatic tissues are likely to encounter protein drugs.   
8.3 The Brain 
Due to the blood brain barrier (BBB), the brain is highly unlikely to receive a 
significant amount of an intravenously administered protein drug.  The blood brain 
barrier refers to a combination of several barriers rather than one contiguous structure.  
Capillary endothelial cells that perfuse the brain possess exceptionally tight occluding 
junctions and phagocytic astrocytes surround these capillaries.  The ependymal cells that 
line the junction between the central nervous tissue and the cerebrospinal fluid also 
possess tight junctions.  Therefore, should an agent leave the capillaries in the brain, it 
must first pass between the endothelial cells (which is nearly impossible), diffuse through 
the endothelial cells (hydrophobic small molecules only), or enter and exit the endothelial 
cells through receptor mediated endocytosis.  The endothelial cells in the blood brain 
barrier present an additional hurdle—several plasma membrane proteins that reject drugs 
(MRP1 and MRP2), proteins, and other disruptive molecules.  The effective molecular 
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weight cutoff of the combined elements of the blood-brain barrier is about 500 Daltons.  
In terms of protein and peptide pharmaceuticals, that amounts to 4-6 amino acids.  Most 
protein drugs are at least ten times larger than this. 
Some proteins can enter the brain through receptor mediated endocytosis, 
including insulin, transferrin, high-density lipoprotein (HDL) and diphtheria toxin (100).  
Some researchers have developed single domain antibodies and other tags that can 
successfully traverse the blood-brain barrier carrying conjugated, therapeutically active 
proteins along with them (101, 102).  There are some areas of neurons that lay outside of 
the blood-brain barrier.  These areas are called circumventricular organs.  Researchers 
seeking to target these areas of the CNS may have less difficulty.  The choroid plexus, 
pineal gland, subfornical organ (thirst center), area postrema (vomiting center), median 
eminence, subcommissural organ, and posterior pituitary gland are all outside of the 
blood-brain barrier.   
The layers of connective tissue surrounding the central nervous system prevent 
diffusion of nearly all molecules from the surrounding interstitium to the nervous tissue 
and cerebrospinal fluid.  From superficial to deep, the layers are known as the dura mater, 
arachnoid mater, and pia mater.   
8.4 The Liver 
The liver is the largest internal organ, receiving roughly 25% of cardiac output in 
normal individuals (Table 10.1).  The liver is a critical component of drug metabolism, 
responsible for the destruction and chemical modification of most drugs.  Protein drugs 
seem to be no exception; many protein drugs are found to accumulate in the liver (29, 30) 
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(103).  This accumulation of proteins is likely due to the phagocytic Kupffer cells of the 
liver, which are responsible for the nonspecific phagocytosis of circulating cellular debris 
and pathogens.   
It is highly likely that non-antigenic peptides and proteins are subject to chemical 
modification in the liver (104).  Supporting evidence can be observed in the elimination 
of large monoclonal antibody fragments, such as the Fab2 studied by Kobayashi et al 
(30).  These antibodies are larger than the exclusion limit in the glomerular charge barrier 
and probably must be cleaved into smaller fragments in order to reach the urinary space 
of the nephrons in the timeframe observed 
8.5 The Kidney 
The human kidney filters the entire blood volume thirty times in one day (assuming 
6 L blood volume, 180 L filtered blood).  Since most protein drugs are intended for 
injection, the concentration of the protein pharmaceutical in the bloodstream reaches its 
zenith almost immediately after injection (intraperitoneal and intramuscular injections are 
slower, but still fast in terms of pharmacokinetics).  Until relatively recently, it was 
believed that the kidney was very efficient at preventing proteins from entering the 
urinary space (105).  The distribution of albumin, a 70 kDa molecule accounting for 
approximately half of the circulating plasma protein, gives insight to the mechanism of 
renal protein metabolism and excretion.  The concentration of albumin in the urine is less 
than 100 mg/dL; however, the concentration of albumin in the ultrafiltrate is 220-320 
mg/dL, which is highly suggestive a proteolytic or endocytotic mechanism for albumin 
reabsorption in the nephron (105).  This mechanism was recently found to be a result of 
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the activity of two proteins present on the brush border of epithelial cells lining the 
nephron: megalin and cubulin (105).  These two proteins were later found to be capable 
of binding many proteins of varying structure (see Fig 1).  In fact, there is evidence that 
the body actually relies on the kidney to destroy certain circulating proteins; patients with 
chronic renal failure develop excessive serum beta-2-microglobulin (106). 
The proteolysis of proteins in the kidney in itself is not a point of contention.  
There are two main issues with renal metabolism/excretion of protein drugs.  First, after 
renal proteolysis, proteins accumulate in the kidney (most likely in the epithelial cells as 
small peptide and amino acid fragments) without being excreted in a timely manner.  
This can be extremely dangerous—many therapeutic proteins under development are 
labeled with radioactive isotopes or other adducts that may be harmful if allowed to 
accumulate in kidney cells. 
8.6 Lymphatic Cells and Tissues 
Obviously the cells responsible for protection against foreign molecules are 
expected to play a role in the fate of exogenous proteins and peptides.  In addition to 
destroying non-self proteins, the lymph nodes, spleen, tonsils, liver and several types of 
loose connective tissues (sub-epithelial layers of hollow organs, tunica adventitia of 
blood vessels, etc.) contain cells that can easily ingest proteins and large particles that are 
not necessarily immunogenic (Fig.11.2).   
The spleen is very well perfused and is the largest collection of lymphoid tissue in 
the body, so it is not surprising that many researchers have found their protein to 
accumulate in the spleen (30, 31).  The spleen exists to activate B and T lymphocytes, 
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remove senescent, damaged and abnormal erythrocytes and platelets, store erythrocytes 
(in some species, but not in humans), and--most relevant to this review—remove 
macromolecules from the blood.  The high perfusion rate of the spleen is coupled with a 
unique sinusoidal circulation large enough to allow the cells to move freely.  The large 
fenestrations are likely a major contributing factor to the high tissue penetration of 
protein drugs in the spleen while the promiscuous phagocytic cells are responsible for the 
accumulation of protein drugs here.   
There are several ways to reduce recognition and opsonization by the diffuse and 
ordered lymphatic tissues.  If at all possible, most of the protein should be humanized.  
Most antibody therapeutics approved by the FDA are chimeric antibodies or humanized 
antibodies.  Before chimeric and humanized antibodies were available, monoclonal 
antibodies generated in nonhuman species were used.  Of course, these provoked a strong 
immune response in patients, greatly diminishing their usefulness.   
Chimeric antibodies are mostly human IgG except for the variable domains.  
Humanized antibodies are advertised as more than 90% human in terms of their peptide 
sequence; only the region responsible for recognition (CDR-complementarity 
determining region) is generated from a non-human species or other means.  This is 
slightly flawed reasoning, as there is a high degree of homology between mouse and 
human antibodies to begin with, so a 100% mouse antibody is quite “human” in most 
regions (107).  Nonetheless, humanization is the optimal means of reducing 
immunogenicity and reducing rapid degradation and accumulation in the lymphatic 
tissues. 
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Some researchers may wish to target the immune system.  For example, anti IL1-
B and anti TNF- antibodies have been used to curb allograft rejection in murine models 
(108).  To specifically target the immune system, the IgGs were encapsulated in 1 µm 
albumin-glutaraldehyde microspheres, which are rapidly ingested by cells of the 
reticuloendothelial system (108, 109).     
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Figure 8.1  Megalin and cubulin.   
Taken from Christensen et al 2003 Pediatric Nephrology 
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Figure 8.2  Some of the phagocytic cells of the body 
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